0001437749-26-006133 | 10-K | XBRL Viewer

Revenue from Contract with Customer [Text Block]

NOTE 2 - REVENUE

As discussed in Note 1, revenues are recognized under the guidance of ASC 606. The following table presents the Company's disaggregated revenue for the periods presented (in thousands):

(in thousands)	*Year ended December 31,*
	*2025*		*2024*		*2023*
Total product revenue, net	$	606,928	$	313,728	$	92,005
License Revenue		152		152		140,153
Milestone Revenue		—		12,500		—
Royalty Revenue		5,615		801		—
Other Revenue		3,592		1,823		1,504
Total Revenue	$	616,287	$	329,004	$	233,662

Product revenue, net

The following table presents the Company's disaggregated BRIUMVI revenue by geography for the periods presented:

(in thousands)	Year ended December 31,
	2025		2024		2023
BRIUMVI
U.S.	$	594,105	$	310,023	$	88,786
International		12,823		3,705		3,219
Worldwide	$	606,928	$	313,728	$	92,005

The Company began shipping BRIUMVI to its U.S. customers in January 2023, and BRIUMVI to its ex-U.S. licensing partner, Neuraxpharm, in November 2023.

As of December 31, 2025, gross-to-net accruals of approximately $20.5 million and $40.9 million are included on the consolidated balance sheets within accounts receivable, net, and accounts payable and accrued expenses, respectively. As of December 31, 2024, gross-to-net accruals of approximately $11.1 million and $20.9 million were included on the consolidated balance sheets within accounts receivable, net, and accounts payable and accrued expenses, respectively.

The Company primarily sells BRIUMVI through specialty distributors. The following table summarizes customers that represented 10% or more of gross product revenue for the years ended December 31, 2025, 2024 and 2023:

	*Twelve months ended December 31,*
	*2025*			*2024*			*2023*
Customer 1		42	%		42	%		41	%
Customer 2		26	%		29	%		31	%
Customer 3		18	%		15	%		16	%
Customer 4		12	%		14	%		13	%

The following table summarizes the customers with amounts due that represent 10% or more of the accounts receivable associated with the Company’s product sales as of December 31, 2025 and 2024:

	*Twelve months ended December 31,*
	*2025*			*2024*
Customer 1		38	%		32	%
Customer 2		18	%		25	%
Customer 3		27	%		25	%
Customer 4		15	%		17	%

License, Milestone, Royalty and Other Revenue

License, milestone, royalty and other revenue consist primarily of recognition of consideration received under the ex-U.S. commercialization agreement (the Commercialization Agreement) with Neuraxpharm. Refer to Note 10 - License Agreements for a description of the Commercialization Agreement and for further information of the accounting in accordance with ASC 606.

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-7

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-9

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-10

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-15

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-13

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org/606/tableOfContent

Note 11 - Related Party Transactions	12 Months Ended
Dec. 31, 2025
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 11 – RELATED PARTY TRANSACTIONS In July 2015, the Company entered into a Shared Services Agreement (the Shared Services Agreement) with FBIO to share the cost of certain services, such as facilities use, personnel costs and other overhead and administrative costs. The Shared Services Agreement requires the Company to pay its respective share of services utilized. In connection with the Shared Services Agreement, the Company incurred expenses of approximately $1.2 million, $1.3 million, and $0.9 million for shared services for the years ended December 31, 2025, 2024 and 2023, respectively, primarily related to shared personnel. Mr. Weiss, the Company's Chairman and Chief Executive Officer, also serves as a director and Executive Vice Chairman, Strategic Development of FBIO. Please refer to Note 8 - Leases for details regarding the Office Agreement with FBIO.

Note 11 - Related Party Transactions

12 Months Ended

Dec. 31, 2025

NOTE 11 – RELATED PARTY TRANSACTIONS

In July 2015, the Company entered into a Shared Services Agreement (the Shared Services Agreement) with FBIO to share the cost of certain services, such as facilities use, personnel costs and other overhead and administrative costs. The Shared Services Agreement requires the Company to pay its respective share of services utilized. In connection with the Shared Services Agreement, the Company incurred expenses of approximately $1.2 million, $1.3 million, and $0.9 million for shared services for the years ended December 31, 2025, 2024 and 2023, respectively, primarily related to shared personnel. Mr. Weiss, the Company's Chairman and Chief Executive Officer, also serves as a director and Executive Vice Chairman, Strategic Development of FBIO.

Please refer to Note 8 - Leases for details regarding the Office Agreement with FBIO.

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-5

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(e))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/850/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-6

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Note 2 - Revenue - Schedules of Concentration of Risk (Details) - Customer Concentration Risk [Member]	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Revenue Benchmark [Member] \| Customer One [Member]
Concentration Risk	42.00%	42.00%	41.00%
Revenue Benchmark [Member] \| Customer Two [Member]
Concentration Risk	26.00%	29.00%	31.00%
Revenue Benchmark [Member] \| Customer Three [Member]
Concentration Risk	18.00%	15.00%	16.00%
Revenue Benchmark [Member] \| Customer Four [Member]
Concentration Risk	12.00%	14.00%	13.00%
Accounts Receivable [Member] \| Customer One [Member]
Concentration Risk	38.00%	32.00%
Accounts Receivable [Member] \| Customer Two [Member]
Concentration Risk	18.00%	25.00%
Accounts Receivable [Member] \| Customer Three [Member]
Concentration Risk	27.00%	25.00%
Accounts Receivable [Member] \| Customer Four [Member]
Concentration Risk	15.00%	17.00%

For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.

+ References + Details

Note 6 - Stockholders' Equity (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended			17 Months Ended
	Dec. 31, 2025	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2025	Sep. 01, 2025	Jun. 12, 2025	Jun. 11, 2025	Aug. 02, 2024	Dec. 31, 2022
Preferred Stock, Shares Authorized (in shares)	10,000,000	10,000,000			10,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.001	$ 0.001			$ 0.001
Common Stock, Shares Authorized (in shares)	190,000,000	190,000,000	190,000,000		190,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.001	$ 0.001	$ 0.001		$ 0.001
Proceeds from Issuance of Common Stock		$ 0	$ 0	$ 46,296
Treasury Stock, Shares, Acquired (in shares)		3,175,740	326,594		3,502,334
Shares Acquired, Average Cost Per Share (in dollars per share)					$ 28.55
Share Repurchase Program, Remaining Authorized, Amount	$ 0	$ 0			$ 0
Treasury Stock, Value, Acquired, Cost Method		$ 91,240	$ 8,760
Treasury Stock, Common, Shares (in shares)	3,543,643	3,543,643	367,903		3,543,643
Treasury Stock, Value	$ 100,234	$ 100,234	$ 8,994		$ 100,234
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)	4,204,816	4,204,816	4,470,216	4,697,029	4,204,816					5,135,685
Share-Based Payment Arrangement, Expense		$ 64,700	$ 42,500	$ 37,900
Warrants to Purchase Common Stock, Amended Loan Agreement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	115,042	115,042			115,042
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 17.95	$ 17.95			$ 17.95
Warrants to Purchase Common Stock, First Amendment Loan Agreement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	50,172	50,172			50,172
Warrants to Purchase Common Stock, First Amendment [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 14.7	$ 14.7			$ 14.7
Stock-based Compensation Expense Capitalized Into Inventory [Member]
Share-Based Payment Arrangement, Expense		$ 3,500	$ 3,800	$ 2,900
Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number (in shares)	12,011,881	12,011,881	11,843,586	9,639,068	12,011,881					8,732,286
Share-Based Payment Arrangement, Expense		$ 63,400	$ 40,100	$ 34,100
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount	$ 42,800	$ 42,800			$ 42,800
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)		2 years 8 months 12 days
Restricted Stock [Member] \| Stock-based Compensation Expense Capitalized Into Inventory [Member]
Share-Based Payment Arrangement, Expense		$ 3,500	3,800	2,900
Milestone Based Restricted Stock [Member]
Share-Based Payment Arrangement, Expense		0
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount	18,600	$ 18,600			18,600
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)		2 years 9 months 18 days
Market-based Restricted Stock [Member]
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount	39,000	$ 39,000			39,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)		2 years 9 months 18 days
Share-Based Payment Arrangement, Option [Member]
Share-Based Payment Arrangement, Expense		$ 1,200	$ 2,500	$ 3,900
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount	$ 400	$ 400			$ 400
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)		7 months 6 days
The 2012 Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)	1,982,316	1,982,316			1,982,316
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)	0	0			0
The 2012 Incentive Plan [Member] \| Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number (in shares)	3,216,638	3,216,638			3,216,638
The 2022 Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)	2,222,500	2,222,500			2,222,500
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)	6,650,149	6,650,149			6,650,149
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)							22,000,000	17,000,000
The 2022 Incentive Plan [Member] \| Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number (in shares)	8,795,243	8,795,243			8,795,243
The 2025 Share Repurchase Program [Member]
Treasury Stock, Shares, Acquired (in shares)	0
Maximum [Member]
Share Repurchase Program, Authorized, Amount									$ 100,000
Maximum [Member] \| The 2025 Share Repurchase Program [Member]
Share Repurchase Program, Authorized, Amount						$ 100,000
The 2022 ATM [Member]
Stock Issued During Period, Shares, New Issues (in shares)		0	0	1,385,700
Proceeds from Issuance of Common Stock				$ 47,100
Shares Issued, Price Per Share (in dollars per share)				$ 34.01
Proceeds from Issuance of Common Stock, Net				$ 46,300

Note 9 - Income Taxes (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%
Operating Loss Carryforward, Tax Expense Allowance	$ 9,500
Deferred Tax Assets, Valuation Allowance	39,977	$ 414,614
Domestic Tax Jurisdiction [Member]
Operating Loss Carryforwards	1,100,000
Domestic Tax Jurisdiction [Member] \| Research Tax Credit Carryforward [Member]
Tax Credit Carryforward, Amount	$ 58,000

Cybersecurity Risk Management and Strategy Disclosure	12 Months Ended
Cybersecurity Risk Management and Strategy Disclosure	Dec. 31, 2025
Cybersecurity Risk Management, Strategy, and Governance [Line Items]
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]	*ITEM 1C.* CYBERSECURITY Risk Management and Strategy** We have implemented and maintain various information security processes designed to mitigate cybersecurity risks, on a case-by-case basis, to our critical computer networks, third party-hosted services, communications systems, hardware and software, and our critical data, including intellectual property, confidential information that is proprietary, strategic or competitive in nature, and data related to patients and clinical trials (IT Assets). The Company’s information security program, which is integrated into our overall risk management processes, evaluates threats posed by internal and external factors and supports daily operational functions that prevent unauthorized access or compromise. Depending on the environment, we implement and maintain various technical, physical, and organizational measures, processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats to our IT Assets, which include implementing policies and guidelines governing the individual use and protection of IT Assets by employees, employee training, and leveraging the capability of third-party service providers to support our internal cybersecurity processes. These processes are aligned with the National Institute of Standards and Technology Cybersecurity Framework (NIST CSF) and the Center for Internet Security Critical Security Controls (CIS Controls). We have implemented and maintain a documented information security incident response plan that is based on the NIST CSF and CIS Controls and is designed to support the identification, escalation, response to, and recovery from cybersecurity incidents in accordance with defined internal procedures and governance processes. The incident response plan is periodically reviewed and tested, and incidents are escalated to appropriate internal stakeholders based on the nature and potential impact of the event. We continue to monitor proposed cybersecurity disclosure rules from the SEC and alter our procedures accordingly. To further improve the effectiveness of our information security processes, we engage third-party service organizations to support monitoring aspects of the Company’s information technology (IT) environment and perform assessments of certain security controls, and provide aggregate, informational monthly reports to our corporate IT Security Team regarding the results of such third-party assessments, training and vulnerability testing, data security posture, identified material cybersecurity risks and areas of improvement. Risks from cybersecurity threats have not materially affected us to date and, based on management's current assessment, are not reasonably likely to materially affect us, our business strategy, results of operations or financial condition. However, the scope and impact of any future cybersecurity incidents cannot be predicted and there can be no assurance that our information security program will be effective in preventing material cybersecurity incidents in the future. For a description of the risks from cybersecurity threats that may materially affect us and how they may do so, see our risk factors under Part 1. Item 1A. Risk Factors in this Annual Report on Form 10-K, including the risk factor captioned “Our internal information technology systems, or those of our third-party CROs, CMOs, or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our drug candidates’ development programs and our commercialization of any products for which we receive regulatory approval.”
Cybersecurity Risk Management Processes Integrated [Flag]	true
Cybersecurity Risk Management Processes Integrated [Text Block]	We have implemented and maintain various information security processes designed to mitigate cybersecurity risks, on a case-by-case basis, to our critical computer networks, third party-hosted services, communications systems, hardware and software, and our critical data, including intellectual property, confidential information that is proprietary, strategic or competitive in nature, and data related to patients and clinical trials (IT Assets).
Cybersecurity Risk Management Third Party Engaged [Flag]	true
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]	true
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]	false
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]	Risks from cybersecurity threats have not materially affected us to date and, based on management's current assessment, are not reasonably likely to materially affect us, our business strategy, results of operations or financial condition. However, the scope and impact of any future cybersecurity incidents cannot be predicted and there can be no assurance that our information security program will be effective in preventing material cybersecurity incidents in the future.
Cybersecurity Risk Board of Directors Oversight [Text Block]	Governance The Board and our Chief Executive Officer are responsible for oversight of the Company’s overall risk management program, including as to cybersecurity related risks, while management is responsible for the day-to-day risk management processes. The Board receives regular reports from our Chief Executive Officer, Chief Financial Officer and other members of management, regarding material cybersecurity threats and risks, effectiveness of our information security processes and status of ongoing cybersecurity initiatives and strategies. Our information technology (IT) team, which is overseen by our Vice President of IT, is responsible for the identification, assessment and management of cybersecurity risks we face and ensuring effective implementation of the Company’s overall cybersecurity efforts. Our Vice President of IT has over 25 years of experience in IT systems, including cybersecurity risk management and incident response, and holds multiple industry-recognized certifications. Our Vice President of IT receives regular reports from the corporate IT Security Team, together with information provided by our third-party service organizations that support monitoring of aspects of the Company’s IT environment, regarding the Company’s material cybersecurity threats and risks and the processes the Company has implemented to address them, which information is reported, as appropriate, to the Chief Financial Officer.
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]	The Board and our Chief Executive Officer are responsible for oversight of the Company’s overall risk management program, including as to cybersecurity related risks, while management is responsible for the day-to-day risk management processes.
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]	The Board receives regular reports from our Chief Executive Officer, Chief Financial Officer and other members of management, regarding material cybersecurity threats and risks, effectiveness of our information security processes and status of ongoing cybersecurity initiatives and strategies. Our information technology (IT) team, which is overseen by our Vice President of IT, is responsible for the identification, assessment and management of cybersecurity risks we face and ensuring effective implementation of the Company’s overall cybersecurity efforts. Our Vice President of IT has over 25 years of experience in IT systems, including cybersecurity risk management and incident response, and holds multiple industry-recognized certifications. Our Vice President of IT receives regular reports from the corporate IT Security Team, together with information provided by our third-party service organizations that support monitoring of aspects of the Company’s IT environment, regarding the Company’s material cybersecurity threats and risks and the processes the Company has implemented to address them, which information is reported, as appropriate, to the Chief Financial Officer.
Cybersecurity Risk Role of Management [Text Block]	The Board receives regular reports from our Chief Executive Officer, Chief Financial Officer and other members of management, regarding material cybersecurity threats and risks, effectiveness of our information security processes and status of ongoing cybersecurity initiatives and strategies. Our information technology (IT) team, which is overseen by our Vice President of IT, is responsible for the identification, assessment and management of cybersecurity risks we face and ensuring effective implementation of the Company’s overall cybersecurity efforts. Our Vice President of IT has over 25 years of experience in IT systems, including cybersecurity risk management and incident response, and holds multiple industry-recognized certifications. Our Vice President of IT receives regular reports from the corporate IT Security Team, together with information provided by our third-party service organizations that support monitoring of aspects of the Company’s IT environment, regarding the Company’s material cybersecurity threats and risks and the processes the Company has implemented to address them, which information is reported, as appropriate, to the Chief Financial Officer.
Cybersecurity Risk Management Positions or Committees Responsible [Flag]	true
Cybersecurity Risk Management Positions or Committees Responsible [Text Block]	The Board receives regular reports from our Chief Executive Officer, Chief Financial Officer and other members of management, regarding material cybersecurity threats and risks, effectiveness of our information security processes and status of ongoing cybersecurity initiatives and strategies. Our information technology (IT) team, which is overseen by our Vice President of IT, is responsible for the identification, assessment and management of cybersecurity risks we face and ensuring effective implementation of the Company’s overall cybersecurity efforts. Our Vice President of IT has over 25 years of experience in IT systems, including cybersecurity risk management and incident response, and holds multiple industry-recognized certifications. Our Vice President of IT receives regular reports from the corporate IT Security Team, together with information provided by our third-party service organizations that support monitoring of aspects of the Company’s IT environment, regarding the Company’s material cybersecurity threats and risks and the processes the Company has implemented to address them, which information is reported, as appropriate, to the Chief Financial Officer.
Cybersecurity Risk Management Expertise of Management Responsible [Text Block]	The Board receives regular reports from our Chief Executive Officer, Chief Financial Officer and other members of management, regarding material cybersecurity threats and risks, effectiveness of our information security processes and status of ongoing cybersecurity initiatives and strategies. Our information technology (IT) team, which is overseen by our Vice President of IT, is responsible for the identification, assessment and management of cybersecurity risks we face and ensuring effective implementation of the Company’s overall cybersecurity efforts. Our Vice President of IT has over 25 years of experience in IT systems, including cybersecurity risk management and incident response, and holds multiple industry-recognized certifications. Our Vice President of IT receives regular reports from the corporate IT Security Team, together with information provided by our third-party service organizations that support monitoring of aspects of the Company’s IT environment, regarding the Company’s material cybersecurity threats and risks and the processes the Company has implemented to address them, which information is reported, as appropriate, to the Chief Financial Officer.
Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]	The Board receives regular reports from our Chief Executive Officer, Chief Financial Officer and other members of management, regarding material cybersecurity threats and risks, effectiveness of our information security processes and status of ongoing cybersecurity initiatives and strategies. Our information technology (IT) team, which is overseen by our Vice President of IT, is responsible for the identification, assessment and management of cybersecurity risks we face and ensuring effective implementation of the Company’s overall cybersecurity efforts. Our Vice President of IT has over 25 years of experience in IT systems, including cybersecurity risk management and incident response, and holds multiple industry-recognized certifications. Our Vice President of IT receives regular reports from the corporate IT Security Team, together with information provided by our third-party service organizations that support monitoring of aspects of the Company’s IT environment, regarding the Company’s material cybersecurity threats and risks and the processes the Company has implemented to address them, which information is reported, as appropriate, to the Chief Financial Officer.
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]	true

Note 1 - Organization and Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities (Details) - shares	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Potentially dilutive securities excluded from calculation (in shares)	16,404,975	15,000,958	13,169,240
Unvested Restricted Stock [Member]
Potentially dilutive securities excluded from calculation (in shares)	12,011,850	10,343,555	8,139,037
Share-Based Payment Arrangement, Option [Member]
Potentially dilutive securities excluded from calculation (in shares)	4,204,816	4,470,216	4,697,029
Warrant [Member]
Potentially dilutive securities excluded from calculation (in shares)	165,214	165,214	312,272
Convertible Debt Securities [Member]
Potentially dilutive securities excluded from calculation (in shares)	23,095	21,973	20,902

Note 4 - Inventory (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Inventory, Noncurrent	$ 15,689	$ 0
Inventory Write-down	6,171	0	$ 0
Inventory Valuation Reserves	6,171	$ (0)
Briumvi Ublituximab [Member]
Inventory Write-down	0
Inventory Valuation Reserves	$ 6,200

Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual) $ in Thousands	12 Months Ended
	Dec. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)
License and Collaboration Agreements, One-time, Non-refundable Payment	$ 616,300
Retained Earnings (Accumulated Deficit)	(1,082,015)	$ (1,529,194)
Cash, Cash Equivalents, and Short-Term Investments	199,500
Restricted Cash and Investments	1,300
Equity Securities, FV-NI	$ 1,323	$ 371
Number of Reportable Segments	1

Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-11

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-11

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-10

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Topic 944
-SubTopic 80
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480078/944-80-55-14

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 944
-SubTopic 80
-Name Accounting Standards Codification
-Section 55
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480078/944-80-55-9

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(1)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(1)(6))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1

U.S. federal statutory income tax rate

Amount of accumulated undistributed earnings (deficit).

+ References + Details

Note 9 - Income Taxes - Reconciliation of Income Tax (Details) - USD ($)
$ in Thousands

12 Months Ended

Dec. 31, 2025

Dec. 31, 2024

Dec. 31, 2023

$ 22,552

$ 5,375

$ 2,743

U.S. federal statutory income tax rate, percent

21.00%

State and local income tax, net of federal income tax effect, amount

$ (6,440)

^[1]

780

(700)

State and local income tax, net of federal income tax effect (a), percent

^[1]

(6.00%)

Research and development (R&D) tax credit, amount

$ (7,352)

(4,637)

(3,402)

Research and development (R&D) tax credit, percent

(6.80%)

Changes in valuation allowance, amount

$ (357,904)

Changes in valuation allowance, percent

(333.30%)

Officer compensation limit, amount

$ 6,213

2,164

(740)

Officer compensation limit, percent

5.80%

Excess tax benefit on stock-based compensation, amount

$ (8,118)

(1,602)

(10,616)

Excess tax benefit on stock-based compensation, percent

(7.60%)

Other nondeductible, amount

$ 324

Other nondeductible, percent

0.30%

Limitation to tax attribute utilization, amount

$ 9,477

Limitation to tax attribute utilization, percent

8.80%

Other tax adjustments, amount

$ 1,459

646

245

Other tax adjustments, percent

1.40%

Income tax (benefit) expense

$ (339,789)

2,211

390

Tax effect and effective tax rate, percent

(316.40%)

Income before income taxes, as reported in the consolidated statements of operations

$ 107,390

25,594

13,062

Research and development credits

(7,352)

(4,637)

(3,402)

Provision-to-return

11,733

(9,235)

Prior period state tax benefit

(3,508)

Other

1,459

646

245

Stock options

$ (8,118)

(1,602)

(10,616)

Change in state tax rates

(4,970)

4,141

Change in the balance of the valuation allowance for deferred tax assets

$ (3,770)

$ 17,954

[1]

State and local income taxes in Kentucky, New York and New York City represent the majority of the tax effect in this category for the year ending December 31, 2025. Tennessee represents the majority of the tax effect in this category for the year ending December 31, 2024. Kentucky represents the majority of the tax effect in this category for the year ending December 31, 2023.

Consolidated Statements of Cash Flows for the Years Ended December 31 - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
CASH FLOWS FROM OPERATING ACTIVITIES
Net income	$ (447,179)	$ (23,383)	$ (12,672)
Adjustments to reconcile net income to net cash used in operating activities:
Loss on extinguishment of debt	0	4,607	0
Noncash stock compensation expense	64,670	42,541	37,933
Depreciation and amortization	59	68	211
Amortization of discount on investment securities	(3,788)	(6,984)	(2,236)
Amortization of debt issuance costs	1,216	1,995	2,378
Amortization of leasehold interest	185	212	212
Deferred income taxes	348,000	0	0
Noncash change in lease liability and right of use asset	1,748	1,900	1,963
Change in fair value of equity investments	298	754	0
Change in fair value of notes payable	27	304	113
Change in inventory reserve	6,171	0	0
Changes in assets and liabilities:
Increase in inventory	(33,452)	(66,851)	(36,938)
Increase in other current assets	(42,430)	(6,316)	(2,831)
Increase in accounts receivable	(176,443)	(78,092)	(51,093)
Increase in accounts payable and accrued expenses	55,878	22,838	192
Decrease in lease liabilities	(2,099)	(2,388)	(2,375)
(Decrease) increase in other current liabilities	(2,381)	4,029	2,675
Increase in deferred revenue	6,390	17,483	5,711
Net cash used in operating activities	(24,772)	(40,517)	(31,413)
CASH FLOWS FROM INVESTING ACTIVITIES
Proceeds from maturity of held-to-maturity securities	237,500	310,900	96,229
Investment in held-to-maturity securities	(222,237)	(310,516)	(146,880)
Investment in equity investments	(1,250)	(1,375)	0
Purchases of Property, Plant and Equipment	(214)	(45)	0
Net cash provided by (used in) investing activities	13,799	(1,036)	(50,651)
CASH FLOWS FROM FINANCING ACTIVITIES
Payment of loan payable	0	(107,553)	0
Issuance of common stock, net	0	0	46,296
Proceeds from exercise of options	1,511	914	1,534
Proceeds from debt financings	0	244,815	25,000
Financing costs paid	0	(889)	(125)
Purchase of treasury stock	(91,240)	(8,760)	0
Net cash (used in) provided by financing activities	(89,729)	128,527	72,705
NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	(100,702)	86,974	(9,359)
CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT BEGINNING OF PERIOD	181,192	94,218	103,577
CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF PERIOD	80,490	181,192	94,218
Reconciliation to amounts on consolidated balance sheets:
Cash and cash equivalents	79,148	179,894	92,933
Restricted Cash	1,342	1,298	1,285
Total cash, cash equivalents and restricted cash	80,490	181,192	94,218
Cash paid for:
Interest	24,249	18,470	8,771
Income taxes	7,879	500	0
NONCASH TRANSACTIONS
Deferred Financing Costs	0	0	1,238
Warrants issued with debt financing	$ 0	$ 0	$ 595

Note 7 - Loan Payable (Tables)

12 Months Ended

Dec. 31, 2025

Schedule of Debt [Table Text Block]

	*The Initial Term Loan*			*The Initial Term Loan*
	*December 31,*			*December 31,*
(in thousands)	*2025*			*2024*
Loan payable	$	250,000		$	250,000
Add: Accreted Liability of final payment fee		—			—
		250,000			250,000
Less: unamortized debt issuance costs		(4,355	)		(5,571	)
		245,645			244,429
Less: principal payments		—			—
Total loan payable		245,645			244,429
Less: current portion		—			—
Loan payable non-current	$	245,645		$	244,429

Note 1 - Organization and Summary of Significant Accounting Policies - Schedule of Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Net income	$ 447,179	$ 23,383	$ 12,672
Weighted-average common shares outstanding (in shares)	144,316,786	145,317,418	141,955,112
Dilutive effect of potential common shares (in shares)	17,095,960	15,018,633	6,553,353
Weighted-average common shares outstanding assuming dilution (in shares)	161,412,746	160,336,051	148,508,465
Net income per share - basic (in dollars per share)	$ 3.1	$ 0.16	$ 0.09
Net income per share - diluted (in dollars per share)	$ 2.77	$ 0.15	$ 0.09

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-9

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-52

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-15

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-7

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-10

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-7

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-9

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-52

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-15

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-7

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-7

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-21

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3A
-Subparagraph (24)(d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-9

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 38: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 39: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 40: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 41: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 42: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 43: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 44: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 46: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 47: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 48: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

Consolidated Statements of Stockholders' Equity for the Years Ended December 31 - USD ($) $ in Thousands	At the Market Offerings [Member] Common Stock [Member]	At the Market Offerings [Member] Additional Paid-in Capital [Member]	At the Market Offerings [Member] Treasury Stock, Common [Member]	At the Market Offerings [Member] Retained Earnings [Member]	At the Market Offerings [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock, Common [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2022						146,426,697
Balance at Dec. 31, 2022						$ 146	$ 1,623,924	$ (234)	$ (1,565,249)	$ 58,587
Balance (in shares) at Dec. 31, 2022								41,309
Issuance of common stock in connection with exercise of options (in shares)						246,156		0		246,156
Issuance of common stock in connection with exercise of options							1,534	$ 0	0	$ 1,534
Issuance of restricted stock (in shares)						3,620,237		0
Issuance of restricted stock						$ 4	(4)	$ 0	0	0
Warrants issued with debt financing							595			595
Forfeiture of restricted stock (in shares)						(213,192)		0
Forfeiture of restricted stock								$ 0	0	0
Issuance of common stock (in shares)	1,385,700		0
Issuance of common stock	$ 1	$ 46,295	$ 0	$ 0	$ 46,296
Compensation in respect of restricted stock granted to employees, directors and consultants						$ 0	40,818	0	0	40,818
Net income						$ 0	0	0	12,672	12,672
Forfeiture of restricted stock								0	0	0
Balance (in shares) at Dec. 31, 2023						151,465,598
Balance at Dec. 31, 2023						$ 151	1,713,162	$ (234)	(1,552,577)	$ 160,502
Balance (in shares) at Dec. 31, 2023								41,309
Issuance of common stock in connection with exercise of options (in shares)						151,813		0		151,813
Issuance of common stock in connection with exercise of options							914	$ 0	0	$ 914
Issuance of restricted stock (in shares)						4,751,729		0
Issuance of restricted stock						$ 5	(5)	$ 0	0	0
Forfeiture of restricted stock (in shares)						(294,773)		0
Forfeiture of restricted stock								$ 0	0	0
Compensation in respect of restricted stock granted to employees, directors and consultants						$ 0	46,325	0	0	46,325
Net income						$ 0	0	$ 0	23,383	23,383
Issuance of common stock in connection with cashless exercise of warrants (in shares)						129,792		0
Issuance of common stock in connection with cashless exercise of warrants								$ 0	0	$ 0
Repurchase of common stock (in shares)						0		326,594		326,594
Repurchase of common stock						$ 0	0	$ (8,760)	0	$ (8,760)
Forfeiture of restricted stock								0	0	0
Balance (in shares) at Dec. 31, 2024						156,204,159
Balance at Dec. 31, 2024						$ 156	1,760,396	$ (8,994)	(1,529,194)	$ 222,364
Balance (in shares) at Dec. 31, 2024								367,903		367,903
Issuance of common stock in connection with exercise of options (in shares)						209,150		0		209,150
Issuance of common stock in connection with exercise of options							1,511	$ 0	0	$ 1,511
Issuance of restricted stock (in shares)						2,822,875		0
Issuance of restricted stock						$ 3	(3)	$ 0	0	0
Forfeiture of restricted stock (in shares)						(386,588)		0
Forfeiture of restricted stock								$ 0	0	0
Compensation in respect of restricted stock granted to employees, directors and consultants						$ 0	68,206	0	0	68,206
Net income						$ 0	0	$ 0	447,179	$ 447,179
Repurchase of common stock (in shares)						0		3,175,740		3,175,740
Repurchase of common stock						$ 0	0	$ (91,240)	0	$ (91,240)
Forfeiture of restricted stock								0	0	0
Balance (in shares) at Dec. 31, 2025						158,849,596
Balance at Dec. 31, 2025						$ 159	$ 1,830,110	$ (100,234)	$ (1,082,015)	$ 648,020
Balance (in shares) at Dec. 31, 2025								3,543,643		3,543,643

Note 6 - Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2025

Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]

				*Weighted-average*
				*grant date fair*
	*Number of shares*			*value*
Outstanding at January 1, 2023		8,732,286			16.12
Granted		3,620,237			13.77
Vested		(2,500,263	)		11.98
Forfeited		(213,192	)		12.14
Outstanding at December 31, 2023		9,639,068			17.05
Granted		4,751,729			18.27
Vested		(2,252,438	)		14.78
Forfeited		(294,773	)		13.49
Outstanding at December 31, 2024		11,843,586			18.22
Granted		2,822,875			30.57
Vested		(2,267,992	)		15.59
Forfeited		(386,588	)		13.33
Outstanding at December 31, 2025		12,011,881		$	21.77

Share-Based Payment Arrangement, Option, Activity [Table Text Block]

						*Weighted-*
						*average*
				*Weighted-*		*contractual*
	*Number of*			*average*		*term*		*Aggregate*
	*shares*			*exercise price*		*(in years)*		*intrinsic value*

Outstanding at January 1, 2023		5,135,685		$	7.10		5.09	$	25,064,799
Granted		—			—
Exercised		(246,156	)		6.08
Forfeited		(192,500	)		11.30
Expired		—			—
Outstanding at December 31, 2023		4,697,029		$	6.98		4.10	$	47,607,209
Granted		—			—
Exercised		(151,813	)		6.02
Forfeited		(75,000	)		13.25
Expired		—			—
Outstanding at December 31, 2024		4,470,216		$	6.90		3.08	$	103,691,060
Granted		—			—
Exercised		(209,150	)		7.22
Forfeited		(56,250	)		12.08
Expired		—			—
Outstanding at December 31, 2025		4,204,816			6.82		2.08	$	96,673,515

Exercisable at December 31, 2025		3,565,226			6.78		2.18	$	82,111,479

Note 6 - Stockholders' Equity

12 Months Ended

Dec. 31, 2025

Shareholders' Equity and Share-Based Payments [Text Block]

NOTE 6 – STOCKHOLDERS’ EQUITY

Preferred Stock

The Company's amended and restated certificate of incorporation authorizes the issuance of up to 10,000,000 shares of preferred stock, $0.001 par value, with rights senior to those of the Company's common stock, issuable in one or more series. Upon issuance, the Company may determine the rights, preferences, privileges and restrictions thereof. These rights, preferences, and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of common stock.

Common Stock

The Company amended and restated its certificate of incorporation authorizes the issuance of up to 190,000,000 shares of $0.001 par value common stock.

In September 2022, the Company entered into an At-the-Market Issuance Sales Agreement (the 2022 ATM) with Cantor Fitzgerald & Co. and B. Riley Securities, Inc. relating to the sale of shares of the Company's common stock. During the year ended December 31, 2023, the Company sold a total of 1,385,700 shares of common stock under the 2022 ATM for aggregate total gross proceeds of approximately $47.1 million at an average selling price of $34.01 per share, resulting in net proceeds of approximately $46.3 million after deducting commissions and other transactions costs. The Company had no activity on the 2022 ATM during the years ended December 31, 2025 and 2024.

On August 8, 2025, the Company filed an automatic “shelf registration” statement on Form S-3 (the 2025 WKSI Shelf) as a WKSI as defined in Rule 405 under the Securities Act of 1933, as amended. The 2025 WKSI Shelf was declared effective upon filing and registers an unlimited amount of debt securities, equity securities, or other securities that the Company may issue and sell from time to time. Accordingly, the 2022 ATM with Cantor Fitzgerald & Co. and B. Riley Securities, Inc. has expired. The Company may offer and sell securities registered under the 2025 WKSI Shelf in one or more offerings, from time to time, depending on market conditions and its capital needs. The Company may also file additional registration statements in the future to maintain financing flexibility in support of its operations.

Share Repurchase Program and Treasury Stock

In August 2024, the Company’s Board of Directors (the Board) authorized a share repurchase program (the Prior Share Repurchase Program) pursuant to which the Company could repurchase up to $100 million of its outstanding common stock. In September 2025, the Company announced the completion of the Prior Share Repurchase Program. Under this program, the Company repurchased an aggregate of 3,502,334 shares of common stock at an average price of $28.55 per share. As of December 31, 2025, no amounts remained available for repurchases under the Prior Share Repurchase Program.

In September 2025, the Board authorized a new share repurchase program (the 2025 Share Repurchase Program) pursuant to which the Company may repurchase up to $100 million of its outstanding common stock. Repurchases under the 2025 Share Repurchase Program may be made from time to time through open market purchases, privately negotiated transactions, or other methods in accordance with applicable federal securities laws, including Rule 10b-18 under the Exchange Act. The 2025 Share Repurchase Program does not have a fixed expiration date, may be suspended or discontinued at any time, and does not obligate the Company to repurchase any specific number of shares. No shares were repurchased under the 2025 Share Repurchase Program during the twelve months ended December 31, 2025.

During the year ended December 31, 2025, the Company repurchased 3,175,740 shares of common stock for an aggregate cost of $91.2 million. As of December 31, 2025, 3,543,643 shares of common stock were held in treasury at an aggregate cost of approximately $100.2 million, representing the fair value of the shares on the dates they were surrendered to the Company, primarily in connection with the Prior Share Repurchase Program.

During the year ended December 31, 2024, the Company repurchased 326,594 shares of common stock for an aggregate cost of $8.8 million. As of December 31, 2024, 367,903 shares of common stock were held in treasury at an aggregate cost of approximately $9.0 million, representing the fair value of the shares on the dates they were surrendered to the Company, primarily in connection with the Company’s share repurchase program.

Equity Incentive Plans

The TG Therapeutics, Inc. Amended and Restated 2012 Incentive Plan (the 2012 Incentive Plan) was approved by stockholders in June 2020. As of December 31, 2025, 3,216,638 shares of restricted stock and 1,982,316 options were outstanding, and no additional shares were available to be issued under the 2012 Incentive Plan.

The TG Therapeutics, Inc. 2022 Incentive Plan (the 2022 Incentive Plan) was approved by stockholders in June 2022 with 17,000,000 shares available to be issued, and was amended to increase the shares available to be issued from 17,000,000 to 22,000,000 in June 2025 (the 2022 Incentive Plan Amendment). As of December 31, 2025, 8,795,243 shares of restricted stock and 2,222,500 options were outstanding, and up to an additional 6,650,149 shares were available to be issued under the 2022 Incentive Plan.

Total stock-based compensation expense included in the consolidated statements of operations was $64.7 million, $42.5 million and $37.9 million during the years ended December 31, 2025, 2024 and 2023, respectively. The $64.7 million, $42.5 million and $37.9 million are net of $3.5 million, $3.8 million, and $2.9 million of stock-based compensation expense that was capitalized into inventory during the years ended December 31, 2025, 2024 and 2023, respectively.

Restricted Stock

Certain employees, directors and consultants have been awarded restricted stock. The vesting terms associated with restricted stock may include service, performance, or market conditions. The following table summarizes restricted share activity for the years ended December 31, 2025, 2024 and 2023:

				*Weighted-average*
				*grant date fair*
	*Number of shares*			*value*
Outstanding at January 1, 2023		8,732,286			16.12
Granted		3,620,237			13.77
Vested		(2,500,263	)		11.98
Forfeited		(213,192	)		12.14
Outstanding at December 31, 2023		9,639,068			17.05
Granted		4,751,729			18.27
Vested		(2,252,438	)		14.78
Forfeited		(294,773	)		13.49
Outstanding at December 31, 2024		11,843,586			18.22
Granted		2,822,875			30.57
Vested		(2,267,992	)		15.59
Forfeited		(386,588	)		13.33
Outstanding at December 31, 2025		12,011,881		$	21.77

Total stock-based compensation expense related to restricted stock grants was $63.4 million, $40.1 million and $34.1 million for the years ended December 31, 2025, 2024 and 2023, respectively, net of $3.5 million, $3.8 million and $2.9 million of expense capitalized into inventory during the years ended December 31, 2025, 2024 and 2023, respectively.

As of December 31, 2025, the Company had approximately $42.8 million of total unrecognized compensation expense related to unvested time-based restricted stock, expected to be recognized over a weighted-average period of 2.7 years.

As of December 31, 2025, the Company had approximately $18.6 million of total unrecognized compensation expense related to unvested milestone-based restricted stock and approximately $39.0 million related to restricted stock with market conditions, which are expected to be recognized over a weighted-average period of 2.8 years.

Milestone-based noncash compensation expense will be recognized if and when achievement of the related milestone becomes probable. Awards with market conditions are valued using advanced option-pricing models, such as a Monte Carlo simulation, with the effect of the market condition reflected in the grant-date fair value. Compensation expense for awards with market conditions is recognized over the requisite service period determined by the grant-date valuation, regardless of whether the market condition is ultimately satisfied.

Stock Options

The Company uses the Black-Scholes option-pricing model when estimating the grant date fair value for the options granted in the years ended December 31, 2025, 2024 and 2023. The following table summarizes stock option activity for the years ended December 31, 2025, 2024 and 2023:

						*Weighted-*
						*average*
				*Weighted-*		*contractual*
	*Number of*			*average*		*term*		*Aggregate*
	*shares*			*exercise price*		*(in years)*		*intrinsic value*

Outstanding at January 1, 2023		5,135,685		$	7.10		5.09	$	25,064,799
Granted		—			—
Exercised		(246,156	)		6.08
Forfeited		(192,500	)		11.30
Expired		—			—
Outstanding at December 31, 2023		4,697,029		$	6.98		4.10	$	47,607,209
Granted		—			—
Exercised		(151,813	)		6.02
Forfeited		(75,000	)		13.25
Expired		—			—
Outstanding at December 31, 2024		4,470,216		$	6.90		3.08	$	103,691,060
Granted		—			—
Exercised		(209,150	)		7.22
Forfeited		(56,250	)		12.08
Expired		—			—
Outstanding at December 31, 2025		4,204,816			6.82		2.08	$	96,673,515

Exercisable at December 31, 2025		3,565,226			6.78		2.18	$	82,111,479

Total stock-based compensation expense associated with stock options was approximately $1.2 million, $2.5 million and $3.9 million during the years ended December 31, 2025, 2024 and 2023, respectively. As of December 31, 2025, there was approximately $0.4 million of total unrecognized compensation cost related to unvested time-based stock options, which is expected to be recognized over a weighted-average period of 0.60 years. As of December 31, 2025, the stock options outstanding include options granted to both employees and non-employees and consist of both time-based and milestone-based awards. Stock-based compensation for milestone-based options will be recorded if and when a milestone becomes probable. The Company did not recognize stock-based compensation expense during the year ended December 31, 2025 for these milestone-based stock options.

Warrants

As of December 31, 2025, the Company had outstanding warrants issued to Hercules Capital, Inc. (Hercules) to purchase 115,042 and 50,172 shares of its common stock with exercise prices of $17.95 and $14.70, respectively. The warrants were issued in connection with the Company's prior loan agreement with Hercules, which has been repaid and terminated. These Warrants shall be exercisable for seven years from their date of issuance, and will expire on December 30, 2028 and March 31, 2030, respectively.

Note 6 - Stockholders' Equity - Summary of Activity for Stock Options (Details) - USD ($)	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Outstanding (in shares)	4,470,216	4,697,029	5,135,685
Outstanding, weighted average exercise price (in dollars per share)	$ 6.9	$ 6.98	$ 7.1
Outstanding, weighted average remaining term (Year)	2 years 29 days	3 years 29 days	4 years 1 month 6 days	5 years 1 month 2 days
Outstanding, intrinsic value	$ 103,691,060	$ 47,607,209	$ 25,064,799
Granted (in shares)	0	0	0
Granted, weighted average exercise price (in dollars per share)	$ 0	$ 0	$ 0
Exercised (in shares)	(209,150)	(151,813)	(246,156)
Exercised, weighted average exercise price (in dollars per share)	$ 7.22	$ 6.02	$ 6.08
Forfeited (in shares)	(56,250)	(75,000)	(192,500)
Forfeited, weighted average exercise price (in dollars per share)	$ 12.08	$ 13.25	$ 11.3
Expired (in shares)	0	0	0
Expired, weighted average exercise price (in dollars per share)	$ 0	$ 0	$ 0
Expired (in shares)	0	0	0
Granted (in shares)	0	0	0
Outstanding (in shares)	4,204,816	4,470,216	4,697,029	5,135,685
Outstanding, weighted average exercise price (in dollars per share)	$ 6.82	$ 6.9	$ 6.98	$ 7.1
Outstanding, intrinsic value	$ 96,673,515	$ 103,691,060	$ 47,607,209	$ 25,064,799
Exercisable (in shares)	3,565,226
Exercisable, weighted average exercise price (in dollars per share)	$ 6.78
Exercisable, weighted average remaining term (Year)	2 years 2 months 4 days
Exercisable, intrinsic value	$ 82,111,479

Note 6 - Stockholders' Equity - Summary of Activity for Restricted Stock (Details) - Restricted Stock [Member] - $ / shares	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Outstanding (in shares)	11,843,586	9,639,068	8,732,286
Outstanding, weighted average grant date fair value (in dollars per share)	$ 18.22	$ 17.05	$ 16.12
Granted (in shares)	2,822,875	4,751,729	3,620,237
Granted, weighted average grant date fair value (in dollars per share)	$ 30.57	$ 18.27	$ 13.77
Vested (in shares)	(2,267,992)	(2,252,438)	(2,500,263)
Vested, weighted average grant date fair value (in dollars per share)	$ 15.59	$ 14.78	$ 11.98
Forfeited (in shares)	(386,588)	(294,773)	(213,192)
Forfeited, weighted average grant date fair value (in dollars per share)	$ 13.33	$ 13.49	$ 12.14
Granted (in shares)	2,822,875	4,751,729	3,620,237
Vested (in shares)	(2,267,992)	(2,252,438)	(2,500,263)
Outstanding (in shares)	12,011,881	11,843,586	9,639,068
Outstanding, weighted average grant date fair value (in dollars per share)	$ 21.77	$ 18.22	$ 17.05

Consolidated Balance Sheets as of December 31 (Parentheticals) - $ / shares	Dec. 31, 2025	Dec. 31, 2024
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized (in shares)	190,000,000	190,000,000
Common stock, issued (in shares)	158,849,596	156,204,159
Common stock, outstanding (in shares)	155,305,953	155,836,256
Treasury stock, shares (in shares)	3,543,643	367,903

Note 7 - Loan Payable

12 Months Ended

Dec. 31, 2025

Long-Term Debt [Text Block]

NOTE 7– LOAN PAYABLE

On August 2, 2024 (the New Closing Date), the Company entered into a term loan facility of $250 million (the Initial Term Loan) with Blue Owl Capital Corporation, as administrative agent (the Administrative Agent), HealthCare Royalty and Blue Owl Capital under the Financing Agreement (as defined below) to repay all outstanding principal and accrued interest and fees under our prior loan agreement with Hercules.

The Initial Term Loan is governed by a financing agreement (the Financing Agreement), which provides for (i) a single draw of the Initial Term Loan, which was funded on August 2, 2024, and (ii) an uncommitted additional facility in an aggregate principal amount of up to $100 million. The Initial Term Loan will mature on August 2, 2029 (the Term Loan Maturity Date). The Initial Term Loan accrues interest at a per annum rate of interest equal to an applicable margin plus, at the Company’s option, either (a) a base rate determined by reference to the highest of (1) the prime rate published by the Wall Street Journal, (2) the federal funds effective rate plus 0.50% and (3) Term SOFR, plus 1.00% or (b) Term SOFR, which shall be no less than 1.00%. The applicable margin for borrowings of the Initial Term Loan is determined on a quarterly basis by reference to a pricing grid based on the achievement of U.S. Net Sales (as defined in the Financing Agreement) for the most recently completed four consecutive fiscal quarters. The pricing grid commences at 5.50% for SOFR borrowings and 4.50% for base rate borrowings and is subject to a 25 basis point step-down upon achievement of a specified U.S. Net Sales threshold. The Initial Term Loan requires scheduled quarterly amortization payments, commencing with the fiscal quarter ending June 30, 2028, in an amount equal to $12.5 million, with the balance due and payable on the Term Loan Maturity Date; provided that such amortization payments may be deferred to the Term Loan Maturity Date upon the achievement of a Total Net Leverage Ratio (as defined in the Financing Agreement) that is less than or equal to an agreed threshold.

The Initial Term Loan is secured by a lien on substantially all of the assets of the Company and by guarantees from certain of the Company's subsidiaries and contains customary covenants and representations. As of December 31, 2025, the Company was in compliance with all financial covenants.

The events of default under the Financing Agreement are customary for financings of this type. If an event of default occurs, the Administrative Agent is entitled to take enforcement action, including acceleration of amounts due under the Financing Agreement.

The Company evaluated whether the Initial Term Loan represented a debt modification or extinguishment of the prior loan agreement with Hercules with ASC 470-50, Debt – Modifications and Extinguishments. As a result of the Initial Term Loan and effective termination of the prior loan agreement with Hercules, this transaction was accounted for by the Company under the extinguishment accounting model. The Company recorded a loss on extinguishment of debt of approximately $4.6 million in the Company’s statement of operations for the three and nine months ended September 30, 2024, representing the write-off of unamortized debt issuance costs and a prepayment charge. The Company capitalized third party fees incurred in connection with the Initial Term Loan to debt issuance costs and capitalized the facility fee incurred with the Administrative Agent as part of the Initial Term Loan to debt discount.

The Company incurred total financing and upfront costs of $6.0 million related to the Initial Term Loan, which are recorded as debt issuance costs and debt discount costs and presented as an offset to loan payable on the Company’s consolidated balance sheet. The debt issuance and debt discount costs are being amortized over the term of the debt using the straight-line method, which approximates the effective interest method, and are included in interest expense in the Company’s consolidated statements of operations. Amortization of debt issuance and debt discount costs was $1.2 million, $2.0 million and $2.4 million for the years ended December 31, 2025, 2024 and 2023, respectively. At December 31, 2025, the remaining unamortized balance of debt issuance and debt discount costs was $4.4 million.

The loan payable balance of the Initial Term Loan as of December 31, 2025 and 2024, is as follows:

	*The Initial Term Loan*			*The Initial Term Loan*
	*December 31,*			*December 31,*
(in thousands)	*2025*			*2024*
Loan payable	$	250,000		$	250,000
Add: Accreted Liability of final payment fee		—			—
		250,000			250,000
Less: unamortized debt issuance costs		(4,355	)		(5,571	)
		245,645			244,429
Less: principal payments		—			—
Total loan payable		245,645			244,429
Less: current portion		—			—
Loan payable non-current	$	245,645		$	244,429

Note 3 - Investment Securities (Tables)

12 Months Ended

Dec. 31, 2025

Debt Securities, Held-to-Maturity [Table Text Block]

	*December 31, 2025*
	*Amortized*		*Gross*		*Gross*
	*cost, as*		*unrealized*		*unrealized*		*Estimated*
(in thousands)	*adjusted*		*holding gains*		*holding losses*		*fair value*
Short-term obligations of domestic governmental agencies (maturing between January 2026 and December 2026) (held-to-maturity)	$	62,822	$	130	$	—	$	62,952
Long-term obligations of domestic governmental agencies (maturing between January 2027 and November 2027) (held-to-maturity)		57,541		201		—		57,742
Total held-to-maturity investment securities	$	120,363	$	331	$	—	$	120,694

	*December 31, 2024*
	*Amortized*		*Gross*		*Gross*
	*cost, as*		*unrealized*		*unrealized*		*Estimated*
	*adjusted*		*holding gains*		*holding losses*		*fair value*
Short-term obligations of domestic governmental agencies (maturing between January 2025 and December 2025) (held-to-maturity)	$	131,106	$	64	$	—	$	131,170
Total held-to-maturity investment securities	$	131,106	$	64	$	—	$	131,170

Tabular disclosure of information about investment in debt security measured at amortized cost (held-to-maturity).

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5B

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (aaa)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (f)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (f)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (f)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5A

Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5A
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5A

Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5A
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5A

Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5B

Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5B
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5B

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5B
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5B

Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5B

Note 1 - Organization and Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2025

Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]

NOTE 1 – ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

DESCRIPTION OF BUSINESS

TG Therapeutics is a fully integrated, commercial stage, biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. The Company also actively evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.

LIQUIDITY AND CAPITAL RESOURCES

Although the Company has recently achieved profitability, it has historically incurred substantial operating losses since its inception and may continue to experience fluctuations in operating results. BRIUMVI was first commercially launched in the United States in January of 2023, and outside the United States through the Company's commercialization partner, Neuraxpharm, in February 2024. Despite the commercialization of BRIUMVI and the potential future commercialization of the Company's other product candidates, there can be no assurance that the Company will maintain profitability on an ongoing basis.

For the twelve months ended December 31, 2025, the Company generated revenue of $616.3 million. The Company's operating results and cash flows have fluctuated in the past and may continue to vary significantly from period to period. The Company will need to generate substantial revenues to sustain profitability and positive cash flow over the long term. Historically, the Company's operating losses have been driven primarily by expenses related to research and development programs and selling, general and administrative costs associated with its operations and commercialization activities to date.

As of December 31, 2025, the Company's accumulated deficit was approximately $1.1 billion, and it had $199.5 million in cash and cash equivalents, and investment securities. Based on its current operating plan and results, the Company anticipates that its existing cash, cash equivalents, and investment securities, together with projected future revenues, will be sufficient to fund operations and meet its liquidity needs for more than twelve months after the date of issuance of this Annual Report on Form 10-K.

The actual level of cash required for operations will depend on numerous factors, including, among others, the scope of commercialization activities for BRIUMVI, the timing of collection of receivables from the Company's customers on extended payment terms, the timing and design of clinical trials for the Company's product candidates, and the costs associated with licensing or acquiring new product candidates. The Company may seek significant additional financing in the future to support strategic initiatives and its ongoing and planned operations.

The Company's common stock is quoted on the Nasdaq Capital Market and trades under the symbol “TGTX.”

RECENTLY ISSUED ACCOUNTING STANDARDS

The Company monitors new accounting pronouncements issued by the Financial Accounting Standards Board (FASB). Management evaluates, and continues to monitor, recently issued but not yet effective accounting pronouncements and does not expect the adoption of such standards to have a material impact on the Company’s consolidated financial statements.

In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (ASU 2023-09). ASU 2023-09 requires entities to provide additional information in their tax rate reconciliation and additional disclosures about income taxes paid by jurisdiction. ASU 2023-09 is effective for annual reporting periods beginning after December 15, 2024, with early adoption permitted. The guidance should be applied prospectively, but entities have the option to apply it retrospectively for each period presented. The Company prospectively adopted this standard in fiscal year 2025, which resulted in incremental income tax disclosures. See Note 9 -Income taxes for further discussion.

In November 2024, the FASB issued ASU No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (ASU 2024-03). ASU 2024-03 requires entities to provide additional disaggregated disclosures of certain income statement expenses, including employee compensation, depreciation, and amortization, within the notes to the financial statements. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The guidance may be applied either prospectively or retrospectively. The Company is currently evaluating the impact that adoption of this new accounting guidance will have on its financial statements.

USE OF ESTIMATES

The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the applicable reporting period. On an ongoing basis, the Company evaluates its estimates and judgments, including those related to revenue, accrued clinical trial expenses, stock-based compensation, inventory valuation, deferred tax asset valuation allowance, and fair value measurement. Actual results could differ from those estimates. Such differences could be material to the Company's results of operations and financial position.

CASH AND CASH EQUIVALENTS

The Company considers liquid investments with original maturities of less than three months from the date of purchase to be cash and cash equivalents.

RESTRICTED CASH

The Company records cash pledged or held in trust as restricted cash. As of December 31, 2025 and 2024, the Company maintained approximately $1.3 million of restricted cash pledged to secure a line of credit as a security deposit for an Office Agreement (see Note 7).

INVESTMENT SECURITIES

Investment securities at December 31, 2025 and 2024 primarily consist of government debt securities. The Company classifies these securities as held-to-maturity. Held-to-maturity securities are those instruments that the Company has the ability and intent to hold until maturity. Held-to-maturity securities are recorded at amortized cost, adjusted for the amortization or accretion of premiums or discounts. Premiums and discounts are amortized or accreted over the life of the related held-to-maturity security as an adjustment to yield using the effective interest method.

A decline in the market value of any investment security below cost that is deemed to be other than temporary results in a reduction in the carrying amount to fair value. The impairment is charged to operations and a new cost basis for the security is established. Other-than-temporary impairment charges are included in interest and other income (expense), net. Dividend and interest income are recognized when earned.

The Company's long-term investments also include approximately $1.3 million of equity securities consisting of common stock of Precision BioSciences, Inc. (Precision). Equity securities are recognized at their fair value in accordance with ASC 321, Investments – Equity Securities. Forward contracts to purchase equity securities that do not qualify as derivatives under ASC 815 are accounted for in accordance with ASC 321. These forward contracts are recorded at fair value at the balance sheet date. See Note 5 for further details.

CREDIT RISK

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and investments. The Company maintains its cash and cash equivalents and investments with high-credit quality financial institutions. At times, such amounts may exceed federally-insured limits, and the Company monitors the creditworthiness of these institutions on an ongoing basis.

REVENUE RECOGNITION

Pursuant to Topic 606, the Company recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration the Company expects to be entitled in exchange for those goods or services. To achieve this core principle, Topic 606 includes provisions within a five-step model that includes (i) identifying the contract with a customer, (ii) identifying the performance obligations in the contract, (iii) determining the transaction price, (iv) allocating the transaction price to the performance obligations, and (v) recognizing revenue when, or as, an entity satisfies a performance obligation.

At contract inception, the Company assesses the goods or services promised within each contract and determine which promised good or service is distinct and therefore considered a performance obligation. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied.

Product Revenue, Net – The Company recognizes product revenues, net of variable consideration related to certain allowances and accruals, when the customer takes control of the product, which is typically upon delivery to the customer. Product revenue is recorded at the net sales price, or transaction price. The Company records product revenue reserves, which are classified as a reduction in product revenues, to account for the components of variable consideration. Variable consideration includes the following components, which are described below: chargebacks, government rebates, commercial payer rebates, trade discounts and allowances, product returns, and co-payment assistance.

These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is expected to be settled with a credit against the Company's customer account) or a liability (if the amount is expected to be settled with a cash payment). The Company's estimate of reserves for variable consideration are calculated using the expected value method, which is the sum of probability-weighted amounts in a range of possible consideration amounts. These estimates reflect the Company's current contractual requirements, customer channel mix, changes to product price, government pricing calculations, and industry data. The amount of variable consideration included in the transaction price may be subject to constraint and is included in net product revenues only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration received may ultimately differ from the Company's estimates. If actual results vary, the Company adjusts these estimates, which could have an effect on earnings in the period of adjustment.

Chargebacks: Chargebacks for discounts represent the Company’s estimated obligations resulting from contractual commitments to sell product to qualified healthcare providers and government agencies at prices lower than the list prices charged to the customers who directly purchase the product from the Company. The customers charge the Company for the difference between what the customers pay the Company for the product and the customers’ ultimate contractually committed or government-required lower selling price to the qualified healthcare providers.

Government Rebates: Government rebates consist of Medicare, Tricare, and Medicaid rebates. These reserves are recorded in the same period the related revenue is recognized. For Medicare, the Company also estimates the number of patients in the prescription drug coverage gap for whom it will owe a rebate under the Medicare Part D program.

Commercial Payer Rebates: The Company contracts with various private payer organizations, primarily insurance companies and pharmacy benefit managers, for the payment of rebates tied to utilization of its product and contracted formulary status. These rebates are estimated and recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability.

Trade Discounts and Allowances: The Company provides its customers with discounts that are explicitly stated in the applicable contracts and are recorded in the period the related product revenue is recognized. In addition, the Company receives sales order management, inventory management, and data services from its customers in exchange for certain fees.

Product Returns: Consistent with industry practice, the Company generally offers customers a limited right of return for product that has been purchased from the Company. The Company estimates the amount of its product sales that may be returned by customers and records this estimate in the period the related product revenue is recognized. The Company currently estimates product return liabilities based on data from similar products and other qualitative considerations, such as visibility into the inventory remaining in the distribution channel.

Subject to certain limitations, the Company’s return policy allows for eligible returns of commercial products sold for credit under the following circumstances:

●	receipt of damaged product;

●	shipment errors that were a result of an error by the Company;

●	expired product that is returned during the period beginning three months prior to the product’s expiration and ending six months after the expiration date;

●	product subject to a recall; and

●	product that the Company, at its sole discretion, has specified can be returned for credit.

As of December 31, 2025, the Company has experienced an immaterial amount of product revenue returns related to sales of BRIUMVI.

Co-Payment Assistance Programs: Co-payment assistance is provided to qualified patients with commercial insurance, whereby the Company may provide financial assistance to patients with prescription drug co-payments required by the patient's insurance provider. Reserves for co-payment assistance are recorded in the same period the related revenue is recognized.

License Agreements –

The Company generates revenue from license or similar agreements with pharmaceutical companies for the development and commercialization of certain products. Such agreements may include the transfer of intellectual property rights in the form of licenses. Payments made by the customer may include non-refundable upfront fees, milestone-based payments, and royalties on sales of products.

Licenses of intellectual property: If a license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to the license as revenue upon transfer of control of the license. All other promised goods or services in the agreement are evaluated to determine if they are distinct. If they are not distinct, they are combined with other promised goods or services to create a bundle of promised goods or services that is distinct.

Milestone payments: Contingent milestones at contract inception are estimated at the amount which is not probable of a material reversal and included in the transaction price using the most likely amount method. Milestone payments that are not within the Company's control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received, and therefore the variable consideration is constrained. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, and the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each reporting period, the Company reevaluates the probability of achieving development or sales-based milestone payments that may not be subject to a material reversal and, if necessary, adjusts the estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which may affect license and other revenue, as well as earnings, in the period of adjustment.

Sales-based royalties: For arrangements that include sales-based royalties and a license of intellectual property that is deemed to be the predominant item to which the royalties relate, revenue is recognized at the later of when the related sales occur or when the performance obligation to which some or all of the royalties have been allocated has been satisfied (or partially satisfied).

Optional Purchases: The Company’s arrangements may provide the licensee the right to make optional purchases of the licensed product. These optional purchases are accounted for as separate contracts when the licensee determines that it will make such a purchase, unless the option conveys a material right. Optional purchases are recorded as product revenue, net.

Other Revenue

Revenue is also generated from service-based fees recognized for providing regulatory support and development services to customers. Service fee revenue is recognized over time as the services are transferred to the customer.

DEFERRED PRODUCT REVENUE

When consideration is received, or such consideration is unconditionally due, from a customer prior to the Company completing its performance obligation under the terms of a contract, a contract liability is recorded as deferred revenue. Deferred revenues expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current liabilities. Deferred revenues not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as long-term liabilities.

ACCOUNTS RECEIVABLE

In general, accounts receivable consists of amounts due from customers, net of customer allowances for cash discounts, product returns, and chargebacks. The Company's standard payment terms for invoiced amounts typically range between 30 – 60 days, however, extended payment terms have been offered during the BRIUMVI commercial launch. The extended payment terms are meant to align with the timing of reimbursement by government and commercial payers and have not adversely affected the collectability of accounts receivable.

In addition, the Company does not adjust accounts receivable for the effects of financing, as the expected time between transfer of the promised products and the payment of the associated consideration is less than one year. The Company analyzes accounts that are past due for collectability, and regularly evaluates the creditworthiness of its customers so that it can properly assess and respond to changes in their credit profiles. As of December 31, 2025, the Company determined that an allowance for expected credit losses related to outstanding accounts receivable was not required because outstanding receivables were due from large, established, credit-worthy customers.

COST OF REVENUE

Cost of revenue consists primarily of royalties owed to the Company's licensing partner for BRIUMVI sales, third-party manufacturing costs, distribution, and overhead. Cost of revenue may also include costs related to excess or obsolete inventory adjustment charges, abnormal costs, unabsorbed manufacturing and overhead costs, and manufacturing variances. All manufacturing costs incurred to produce BRIUMVI prior to the approval of BRIUMVI by the FDA were expensed to research and development and therefore are not reflected in the cost of revenue. Therefore, a portion of costs incurred to produce BRIUMVI that were sold through the middle of the quarter ended March 31, 2025 had previously been expensed as research and development and are not reflected in the Company's cost of revenue. Costs related to providing regulatory support and development services to the Company's ex-U.S. commercialization partner, Neuraxpharm, are included in the Company's cost of revenue.

INVENTORY

Inventories are stated at the lower of cost or estimated net realizable value, with cost based on the first-in-first-out method (FIFO). The Company classifies inventory costs as long-term inventory in its consolidated balance sheets, when the Company expects to utilize the inventory beyond its normal operating cycle. Prior to regulatory approval, the Company expenses costs relating to the production of inventory as research and development expense in the period incurred. Following regulatory approval, costs to manufacture those approved products are capitalized. Inventory that can be used in either the production of clinical or commercial products is expensed as research and development costs when identified for use in clinical trials. Prior to the approval of BRIUMVI, all manufacturing and other potential costs related to the commercial launch of BRIUMVI were expensed to research and development in the period incurred.

RESEARCH AND DEVELOPMENT COSTS

Generally, research and development costs are expensed as incurred. Research and development expenses consist primarily of costs incurred with third-party service providers for the conduct of research, preclinical and clinical studies, contract manufacturing costs, license milestone fees, personnel costs for the Company's research and development employees, consulting, and other related expenses. The Company recognizes research, preclinical and clinical study expenses based on services performed, pursuant to contracts with third-party research and development organizations that conduct and manage research, preclinical and clinical activities on the Company's behalf.

The Company accrues these expenses based on the progress or stage of completion of services and the contracted fees to be paid for such services. If the actual timing of the performance of services or the level of effort varies from the original accrual, the Company adjusts the accrual accordingly. With respect to clinical trial costs, the financial terms of these agreements are subject to an initial negotiation and vary from contract to contract. Payments under these contracts may be uneven and depend on factors such as the achievement of certain events, the successful recruitment of patients, the completion of portions of the clinical trial, or similar conditions. As such, certain expense accruals related to clinical site costs are recognized based on the degree of performance of the event or events specified in the specific clinical study or trial contract.

INCOME TAXES

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, as well as operating losses and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. If the likelihood of realizing the deferred tax assets or liabilities is less than “more likely than not,” a valuation allowance is recorded.

The Company, and its subsidiaries, file income tax returns in the U.S. federal jurisdiction and in various states. The Company has tax net operating loss carryforwards that are subject to examination for a number of years beyond the year in which they were generated for tax purposes. Since a portion of these net operating loss carryforwards may be utilized in the future, many of these net operating loss carryforwards will remain subject to examination. The Company recognizes interest and penalties related to uncertain income tax positions in income tax expense. Refer to Note 9 for further information.

STOCK-BASED COMPENSATION

Stock-based compensation costs related to equity awards granted to employees and non-employees are measured at the date of grant based on the fair value of the award. The Company estimates the grant date fair value of options, and the resulting stock-based compensation expense, using the Black-Scholes option-pricing model. Equity awards with market conditions are valued using advanced option-pricing models, such as a Monte Carlo simulation, with the effect of a market condition reflected in the award’s fair value on the grant date. For time-based or performance-based restricted stock, the fair value is based on the market value of the Company's common stock on the date of grant.

Stock-based compensation expense for time-based restricted stock and options is recognized on a straight-line basis over the requisite service period. Stock-based compensation expense for awards that vest upon the achievement of milestones is recognized over the requisite service period when the achievement of such milestones becomes probable. Stock-based compensation expense for an award that has a market condition is recognized over the requisite service period, which is derived from the valuation model, even if the market condition is never satisfied. The Company recognizes all stock-based payments to employees and non-employee directors (as compensation for service) as noncash compensation expense in the consolidated financial statements. The Company recognizes forfeitures as they occur.

SHARE REPURCHASES

The Company repurchases shares through open market purchases, privately-negotiated transactions, block purchases, or otherwise in accordance with applicable federal securities laws, including Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the Exchange Act). The Company accounts for shares repurchased under the treasury accounting method (ASC 505-30). The Company recognizes the amount paid to repurchase the shares as a reduction of stockholders’ equity and includes treasury stock on a separate line item in the equity section of the Company's consolidated balance sheet. Treasury stock is excluded from shares outstanding.

NET INCOME PER COMMON SHARE

Basic net income per share of the Company's common stock is calculated by dividing net income applicable to the common stock by the weighted-average number of the Company's common stock outstanding for the period. Diluted net income per share of common stock reflects the effect of potential common shares from the assumed exercise or conversion of securities such as warrants, stock options, and restricted stock, to the extent they are dilutive. For all periods presented, the Company reported net income in the consolidated statements of operations and, accordingly, present the dilutive effect of potential common shares in the computation of diluted earnings per share, as shown in the table below.

The following table summarizes the Company's potentially dilutive securities at December 31, 2025, 2024 and 2023:

	*December 31,*
	*2025*		*2024*		*2023*
Unvested restricted stock		12,011,850		10,343,555		8,139,037
Options		4,204,816		4,470,216		4,697,029
Warrants		165,214		165,214		312,272
Shares issuable upon note conversion		23,095		21,973		20,902
Total		16,404,975		15,000,958		13,169,240

The computation of basic and diluted earnings per share (EPS) is as follows:

	*Year ended*
	*December 31,*
(in thousands, except share and per share data)	*2025*		*2024*		*2023*
Net income		447,179		23,383		12,672
Weighted-average common shares outstanding		144,316,786		145,317,418		141,955,112
Dilutive effect of potential common shares		17,095,960		15,018,633		6,553,353
Weighted-average common shares outstanding assuming dilution		161,412,746		160,336,051		148,508,465

Net income per share - basic		3.10		0.16		0.09
Net income per share - diluted		2.77		0.15		0.09

LONG-LIVED ASSETS AND GOODWILL

Long-lived assets are reviewed for potential impairment when circumstances indicate that the carrying value of long-lived tangible and intangible assets with finite lives may not be recoverable. Management’s assessment in determining whether an impairment indicator or triggering event exists, includes an evaluation of both quantitative, measurable operating performance criteria and qualitative measures. If an analysis is necessitated by the occurrence of a triggering event, the Company uses certain assumptions in estimating the impairment amount, such as expected future cash flows and other factors. If the carrying amount of an asset exceeds its estimated future undiscounted cash flows, an impairment charge is recognized to reduce the asset to its fair value.

Goodwill represents the excess consideration transferred in a business combination over the fair value of identifiable net assets acquired. Goodwill is not amortized but is reviewed for impairment at least annually, or more frequently if events or changes in circumstances indicate that impairment indicators may be present. The Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. If this qualitative assessment indicates that impairment is more likely than not, the Company performs a quantitative test comparing the reporting unit's fair value with its carrying value to determine the amount of any impairment.

LEASES

All leases with a lease term greater than 12 months, regardless of lease classification, are recorded as a lease liability on the balance sheet with a corresponding right-of-use (ROU) asset. Operating leases are reflected as lease liabilities on the commencement date of the lease based on the present value of the lease payments to be made over the lease term. Current operating lease liabilities are reflected in lease liabilities – current portion and noncurrent operating lease liabilities are reflected in lease liabilities – non-current on the consolidated balance sheet.

Right-of-use assets are initially measured based on the lease liability, plus any initial direct costs or rent prepayments, minus lease incentives and any deferred lease payments. Operating lease ROU assets are recorded in right-of-use assets on the consolidated balance sheet, and lease cost is recognized on a straight-line basis over the lease term.

Leases with an initial term of 12 months or less are not recorded on the balance sheet, and the Company recognizes lease expense for these leases on a straight-line basis over the lease term.

In determining whether a contract contains a lease, the Company evaluates asset and service agreements at inception and upon modification to identify specifically identifiable assets, and to determine whether the arrangement conveys the right to control and obtain substantially all of the economic benefits from those assets.

SEGMENT REPORTING

Operating segments are defined as components of an enterprise that engage in business activities from which it may recognize revenues and incur expenses, and for which discrete financial information is available and is evaluated regularly by the chief operating decision maker (CODM) to allocate resources and assess performance.

The Company operates as a single reportable segment, focused on B-cell mediated disease therapy, which includes all activities related to the development and commercialization of novel treatments, including BRIUMVI, to address unmet medical needs and improve the lives of patients. The determination of a single reportable segment is consistent with the consolidated financial information regularly provided to the Company’s CODM, which is its chief executive officer, who evaluates financial results and operating metrics, specifically consolidated net income, for purposes of assessing performance, making operating decisions, allocating resources and planning and forecasting for future periods. The measure of segment assets reported to the CODM corresponds to the total assets presented on the Company's consolidated balances sheets.

Note 10 - License Agreements

12 Months Ended

Dec. 31, 2025

License Agreement Disclosure [Text Block]

NOTE 10 – LICENSE AGREEMENTS

BRIUMVI (Ublituximab)

In January 2012, the Company entered into an exclusive license agreement with LFB Biotechnologies, GTC Biotherapeutics and LFB/GTC LLC, all wholly-owned subsidiaries of LFB Group, relating to the development of ublituximab (the LFB License Agreement). Under the terms of the LFB License Agreement, the Company acquired the exclusive worldwide rights (exclusive of France/Belgium) for the development and commercialization of ublituximab. From the inception of the LFB License Agreement, the Company incurred expenses of approximately $31.0 million related to the achievement of certain milestones under the LFB License Agreement. These expenses are included in other research and development expenses in the accompanying consolidated statements of operations. No further milestone payments remain payable under the LFB License Agreement.

LFB Group is eligible to receive royalty payments on net sales of ublituximab at a royalty rate that escalates from mid-single digits to high-single digits. The license will terminate on a country-by-country basis upon the expiration of the last licensed patent right or fifteen years after the first commercial sale of a product in such country, unless the agreement is earlier terminated (i) by LFB if the Company challenges any of the licensed patent rights, (ii) by either party due to a breach of the agreement, or (iii) by either party in the event of the insolvency of the other party. During the years ended December 31, 2025, 2024 and 2023, the Company recorded $61.3 million, $30.7 million, and $8.7 million, respectively, related to the worldwide royalty due under the LFB License Agreement in cost of revenue based on U.S. sales of BRIUMVI. As of December 31, 2025, approximately $19.2 million in royalties payable under the LFB License Agreement remained outstanding in accounts payable and accrued expenses.

In November 2012, the Company entered into an exclusive (within the territory) sublicense agreement with Ildong Pharmaceutical Co. Ltd. (Ildong) relating to the development and commercialization of ublituximab in South Korea and Southeast Asia. Under the terms of the sublicense agreement, Ildong was granted a royalty bearing, exclusive right, including the right to grant sublicenses, to develop and commercialize ublituximab in South Korea, Taiwan, Singapore, Indonesia, Malaysia, Thailand, Philippines, Vietnam, and Myanmar.

An upfront payment of $2.0 million, which was received in December 2012, net of $0.3 million of income tax withholdings, is recognized as license revenue on a straight-line basis over the life of the agreement, which is through the expiration of the last licensed patent right or fifteen years after the first commercial sale of a product in such country, unless the agreement is earlier terminated, and represents the estimated period over which the Company has certain ongoing responsibilities under the sublicense agreement. The Company recorded license revenue of approximately $0.2 million for each of the years ended December 31, 2025, 2024 and 2023. At December 31, 2025 and 2024, the Company had deferred revenue of zero and $0.2 million, respectively, associated with this $2 million payment.

The Company may receive up to an additional $5.0 million in payments upon the achievement of pre-specified milestones. In addition, upon commercialization, Ildong will be required to make royalty payments to the Company on net sales of ublituximab in the sublicense territory.

Neuraxpharm Commercialization Agreement

In July 2023, the Company entered into the Commercialization Agreement with Neuraxpharm. The Company granted Neuraxpharm the exclusive right to commercialize BRIUMVI in certain territories outside the United States, Canada, and Mexico, the commercialization rights for which had been previously retained by the Company, thus, and excluding certain Asian countries subject to previously existing partnerships. Under the terms of the Commercialization Agreement, the Company received a one-time, non-refundable payment of $140.0 million upon contract execution and a $12.5 million milestone payment upon the first key market commercial launch in the EU. The Company is eligible to receive up to an additional $492.5 million in milestone-based payments upon achievement of certain launch and commercial milestones. In addition, the Company will receive tiered double-digit royalties on net product sales up to 30%. During the years ended December 31, 2025 and 2024, royalty revenue of $5.6 million and $0.8 million, respectively, was recognized.

The Company evaluated the Commercialization Agreement under ASC 606 and concluded that Neuraxpharm represents a customer in the transaction. In accordance with this guidance, the Company identified the following commitments under the arrangement: (i) the exclusive right to develop, sell, offer to sell and import the Product in the Territory (the License); (ii) certain development and regulatory activities (the Development and Regulatory Activities).

The arrangement also provides Neuraxpharm with the right to make optional purchases of BRIUMVI (the Supply of Licensed Product). These optional purchases are accounted for as a separate contract when the right to purchase BRIUMVI is exercised. The consideration for optional purchases approximates a market-based price for BRIUMVI by Neuraxpharm in the Territory. The consideration received for optional purchases is generally received in advance of shipment and is recognized by the Company as deferred revenue until the related performance obligation is met. The performance obligation is met when control of the product passes to Neuraxpharm, at which time the optional purchases are recognized as a component of product revenue, net.

As of December 31, 2025, the Company had $30.0 million of deferred revenue related to optional purchases for which the performance obligation had not been met. This includes $1.8 million recorded in accounts receivable, net for consideration the Company has an unconditional right to receive from Neuraxpharm under the Commercialization Agreement. The Company reevaluates the consideration received, and performance obligations satisfied, at the end of each reporting period. Such reevaluations may result in a change to the amount of product revenue, net, recognized and deferred revenue.

Azer-cel

In January 2024, the Company and its wholly-owned subsidiary, TG Cell Therapy, Inc., entered into the Precision License Agreement with Precision, pursuant to which Precision granted the Company certain exclusive and non-exclusive license rights to develop, manufacture, and commercialize Precision’s allogeneic CAR T therapy azercabtagene zapreleucel (azer-cel) for the treatment of autoimmune and other non-oncology diseases and conditions.

Pursuant to the Precision License Agreement, the Company made an upfront payment to Precision of $7.5 million, consisting of (i) $5.25 million in cash and (ii) $2.25 million, as an equity investment, for the purchase of 2,920,816 shares of Precision’s common stock. In January 2025, the Company made a deferred payment of $2.5 million to Precision consisting of an equity investment in Precision’s common stock at a 100% premium to the 30-day volume-weighted average price (the 30-day VWAP) prior to purchase. Upon achievement of certain near-term clinical or time-based milestones, the Company will make a $7.5 million payment to Precision, a portion of which will also be an equity investment in Precision’s common stock at a 100% premium to the 30-day VWAP prior to purchase.

Precision will be eligible to receive up to $288 million in additional milestone payments based on the achievement of certain clinical, regulatory, and commercial milestones. In addition, the Company is obligated to pay Precision high-single-digit to low-double-digit royalties on net sales of the licensed product on a country-by-country basis until the latest to occur of patent expiration, loss of regulatory exclusivity, and a period of ten years following the first commercial sale of the licensed product in such country. As of December 31, 2025, none of the near-term clinical milestones have been achieved.

MaxCyte

On February 10, 2025, the Company entered into the Strategic Platform License Agreement with MaxCyte, Inc (MaxCyte). which granted a non-exclusive, non-transferable license for the Company to use MaxCyte’s cell loading technology (licensed technology) to develop and commercialize products for the treatment of autoimmune and other non-oncology diseases and conditions, including azer-cel, licensed by the Company from Precision in January 2024.

MaxCyte is eligible to receive royalty payments on net sales of approved products developed with the licensed technology at a royalty rate in the low-single digits. Upon the achievement of the first dosing of a human subject in a pivotal trial for a product developed with the licensed technology the Company will make a $1.0 million payment to MaxCyte. MaxCyte is also eligible to receive up to $13.0 million in additional milestone payments based on the achievement of certain regulatory marketing approvals. The Company is required to pay an annual licensing fee of approximately $0.2 million for access to the licensed technology.

The Strategic Platform License Agreement expires on the ten-year anniversary unless the Company achieves at least one of the milestone events prior to that date. The Company has the option, at its sole discretion, to extend the term of the Strategic Platform License Agreement beyond the initial ten years for successive renewal terms of five years each, as long as all applicable licensing fees and milestone payments are paid timely and the Company provides MaxCyte at least ninety days written notice prior to the expiration of the then-current term.

TG-1701: BTK

In January 2018, the Company entered into a global exclusive license agreement with Jiangsu Hengrui Medicine Co. (Hengrui), to acquire worldwide intellectual property rights, excluding Asia but including Japan, for the research, development, manufacturing, and commercialization of products containing or comprising any of Hengrui’s Brutons Tyrosine Kinase inhibitors, containing the compounds of TG-1701. In September 2025, the Company and Jiangsu mutually agreed to terminate the license agreement for TG-1701. As a result, all rights to the program reverted to Jiangsu, and the Company has no further obligations for milestone or royalty payments.

TG-1801: anti-CD47/anti-CD19

In June 2018, the Company entered into a Joint Venture and License Option Agreement with Novimmune SA (Novimmune) to collaborate on the development and commercialization of Novimmune’s novel first-in-class anti-CD47/anti-CD19 bispecific antibody known as TG-1801 (previously NI-1701). In April 2025, the Company and Novimmune mutually agreed to terminate the Joint Venture and License Option Agreement. As a result, all rights to the program reverted to Novimmune, and the Company has no further obligations for milestone or royalty payments.

Note 9 - Income Taxes - Components of Income Tax Provision (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Current:
Federal	$ 0	$ 0	$ 0
State	8,211	2,211	390
Foreign	0	0	0
Total current tax expense	8,211	2,211	390
Deferred:
Federal	(335,077)	0	0
State	(12,923)	0	0
Foreign	0	0	0
Total deferred tax (benefit) expense	(348,000)	0	0
Income tax (benefit) expense	$ (339,789)	$ 2,211	$ 390

Note 4 - Inventory

12 Months Ended

Dec. 31, 2025

Inventory Disclosure [Text Block]

NOTE 4 – INVENTORY

The following table presents the Company's inventory as of December 31, 2025 (in thousands):

	*December 31, 2025*			*December 31, 2024*
Raw Materials	$	12,960		$	28,151
Work in Process		112,397			68,369
Finished Goods		22,089			13,938
Inventory, gross		147,446			110,458
Inventory Reserve		(6,171	)		—
Inventory, net	$	141,275		$	110,458

Reported As:
Inventory	$	125,586		$	110,458
Long-term Inventory		15,689			—
Total Inventory	$	141,275		$	110,458

Inventory is stated at the lower of cost or net realizable value and consists of raw materials, work-in-process, and finished goods. Cost is determined using a standard cost method, which approximates actual cost, and assumes a FIFO flow of goods. Inventory that is used for clinical development purposes is expensed to research and development in the period in which it is consumed.

At December 31, 2025 and 2024, the Company's inventory was solely related to BRIUMVI. The work in process materials consist primarily of bulk drug substance, which has a multi-year shelf life. When the bulk drug substance is manufactured into BRIUMVI finished goods, those finished goods have a shelf life of three years from the date of manufacture. The Company expects to sell finished goods at least twelve months prior to expiration. The Company completed its evaluation of the length of our normal operating cycle and determined a portion of inventory will be utilized beyond our normal operating cycle. Therefore, during the quarter ended December 31, 2025, $15.7 million of inventory comprised predominantly of raw materials is now classified as Long-term Inventory.

On a quarterly basis, the Company analyzes its inventory levels for excess quantities and obsolescence (expiration) by considering factors, such as historical and anticipated future sales relative to quantities on hand and the remaining shelf-life. At December 31, 2025 and 2024, the Company determined that a reserve related to BRIUMVI inventory for excess quantities and obsolescence was not required. In addition, since FDA approval of BRIUMVI, the Company has not recognized any inventory write downs.

In September 2025, the Company identified a potential manufacturing deviation affecting one batch of bulk drug substance. As a result of the Company’s continued evaluation of the impact of this deviation on product usability, it was determined that a loss was probable. Therefore, as of December 31, 2025, the Company recorded a $6.2 million inventory reserve related to this matter in accordance with ASC 450-20 as management had determined that a loss was both probable and could be reasonably estimated.

The United States and other countries have recently imposed, and may continue to impose, new tariffs. Tariffs are an inventoriable cost, and the Company's sole supplier of bulk drug substance is located outside of the U.S. While the tariffs imposed to date have not had a material effect on the Company's business or results of operations, the Company continues to evaluate their potential impact on its business and results of operations going forward.

Note 8 - Leases - Schedule of Classification of Lease Liabilities (Details) - USD ($)
$ in Thousands

Dec. 31, 2025

Dec. 31, 2024

$ 2,080

1,913

1,827

1,827

2,889

10,536

(2,471)

Present value of lease liabilities(*)

$ 8,065

^[1]

$ 9,290

[1]

As the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date and considering the term of the lease to determine the present value of lease payments. The Company used the incremental borrowing rate of 10.25% on February 28, 2019, for operating leases that commenced prior to that date through December 31, 2021. The Company used an incremental borrowing rate of 5.65% for the NC lease.

Note 5 - Fair Value Measurements

12 Months Ended

Dec. 31, 2025

Fair Value Disclosures [Text Block]

NOTE 5 – FAIR VALUE MEASUREMENTS

The Company measures certain financial assets and liabilities at fair value on a recurring basis in its financial statements. The fair value hierarchy ranks the quality and reliability of inputs, or assumptions, used to determine fair value and requires financial assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:

●

Level 1 – quoted prices in active markets for identical assets and liabilities;

●

Level 2 – inputs other than Level 1 quoted prices that are directly or indirectly observable; and

●

Level 3 – unobservable inputs for which market data are not available.

Equity Investments and Forward Contract Liabilities

In January 2024, the Company and its wholly-owned subsidiary, TG Cell Therapy, Inc., (TG Cell) entered into a License Agreement (the Precision License Agreement) with Precision. Under the agreement, Precision granted the Company certain exclusive and non-exclusive license rights to develop, manufacture, and commercialize Precision’s allogeneic CAR T therapy, azer-cel, for the treatment of autoimmune and other non-oncology diseases and conditions.

Upon execution of the Precision License Agreement, the Company made an upfront payment to Precision of $7.5 million, comprised of (i) $5.25 million in cash and (ii) $2.25 million (the Upfront Precision Stock Payment), as an equity investment, for the purchase of 2,920,816 shares of Precision’s common stock at a price of $0.77 per share. The Company paid a premium for the shares, which was recorded in research and development expense as part of the cost of the Precision License Agreement. Precision subsequently implemented a 30-to-1 reverse stock split in February 2024.

On January 7, 2025, the Company made a one-time payment to Precision equal to $2.5 million (the Deferred Precision Stock Payment), as an equity investment, for the purchase of 220,712 shares of Precision common stock calculated by dividing the Deferred Precision Stock Payment by 200% of the weighted average share price of the Precision common stock for the thirty (30) trading days preceding the payment date. The Deferred Precision Stock Payment, which had previously been classified as a forward contract liability in other current liabilities as of December 31, 2024, was reclassified to equity investments at its fair market value of $1.4 million on the date the payment was made to Precision.

All Precision shares held are recognized at fair market value as of December 31, 2025, and are classified as an equity investment and included within long-term investments on the consolidated balance sheets as of December 31, 2025.

The Precision License Agreement also includes a milestone payment upon the achievement of a clinical and regulatory milestone event (Milestone Event 1). Upon achievement of Milestone Event 1, the Company is required to make a one-time payment to Precision equal to $2.3 million (the Milestone 1 Precision Stock Payment), in exchange for shares of Precision common stock (rounded down to the nearest whole share) calculated in the same manner as the Deferred Precision Stock Payment. While Milestone Event 1 has not been achieved, the obligation was recognized in research and development license fees upon execution of the agreement and is classified as a forward contract liability measured at its fair market value. In accordance with ASC 321, the Milestone 1 forward liability was recorded at $1.4 million in other current liabilities on the Company’s consolidated balance sheets as of December 31, 2025.

5% Notes

At the time of the Company's merger (the Company was then known as Manhattan Pharmaceuticals, Inc. (Manhattan)) with Ariston Pharmaceuticals, Inc. (Ariston) in March 2010, Ariston issued $15.5 million of five-year 5% notes payable (the 5% Notes) in satisfaction of several prior note payable issuances. The 5% Notes and accrued and unpaid interest thereon are convertible at the option of the holder into common stock at the conversion price of $1,125 per share. The Company has no obligations associated with the 5% Notes other than the conversion feature. The 5% Notes are recognized in other current liabilities on the Company’s consolidated balance sheets as of December 31, 2025, as the notes are currently convertible and therefore classified as short-term obligations.

The Company’s financial instruments include cash, cash equivalents consisting of money market funds, accounts receivable, accounts payable and loan payable. As of December 31, 2025 and 2024, the fair values of cash and cash equivalents, restricted cash, accounts receivable, and loan and interest payable approximated their carrying value due to their short term nature. The carrying value of the loan payable on the Company’s balance sheet is also estimated to approximate its fair value, as the interest rate is aligned with market rates for instruments with similar terms and risk characteristics.

The following tables provide the fair value measurements of applicable financial assets and liabilities as of December 31, 2025 and 2024:

	*Financial liabilities at fair value as of December 31, 2025*
(in thousands)	*Level 1*		*Level 2*		*Level 3*		*Total*

Equity Investments	$	1,323	$	—	$	—	$	1,323
Total Assets	$	1,323	$	—	$	—	$	1,323

Forward Contract Liabilities		—		1,412		—		1,412
5% Notes	$	—	$	—	$	689	$	689
Total	$	—	$	1,412	$	689	$	2,101

	Financial liabilities at fair value as of December 31, 2024
	Level 1		Level 2		Level 3		Total

Equity Investments	$	371	$	—	$	—	$	371
Total Assets	$	371	$	—	$	—	$	371

Forward Contract Liabilities	$	—	$	3,129	$	—	$	3,129
5% Notes	$	—	$	—	$	661	$	661
Total Liabilities	$	—	$	3,129	$	661	$	3,790

The Company's equity investments classified as Level 1 were valued using their respective closing stock prices on the Nasdaq Stock Market, which represents unadjusted quoted prices in active markets for identical instruments. The Company did not experience any transfers of financial instruments between the fair value hierarchy levels during the year ended December 31, 2025 and 2024.

The Company's forward contract liabilities classified as Level 2 were valued using Precision's closing stock price on the Nasdaq Stock Market.

The Company's Level 3 instrument amounts represent the fair value of the 5% Notes and related accrued interest, as certain inputs to determine fair value were unobservable.

The change in the fair value of the Level 1 assets and Level 2 and Level 3 liabilities is recognized in other (income) expense in the accompanying consolidated statements of operations.

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 107
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-107

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 940
-SubTopic 820
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478119/940-820-50-1

Note 4 - Inventory - Schedule of Inventory (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Raw Materials	$ 12,960	$ 28,151
Work in Process	112,397	68,369
Finished Goods	22,089	13,938
Inventory, gross	147,446	110,458
Inventory Reserve	(6,171)	0
Inventory, net	141,275	110,458
Inventory	125,586	110,458
Long-term Inventory	$ 15,689	$ 0

Note 8 - Leases

12 Months Ended

Dec. 31, 2025

Lessee, Operating Leases [Text Block]

NOTE 8– LEASES

In October 2014, the Company entered into an agreement (the Office Agreement) with Fortress Biotech, Inc. (FBIO) to occupy approximately 45% of the 24,000 square feet of New York City office space leased by FBIO. The Office Agreement requires the Company to pay its respective share of the average annual rent and other costs of the 15-year lease. The Company estimates an average annual rental obligation of $1.8 million under the Office Agreement. In connection with the Office Agreement, the Company pledged $1.3 million to secure a line of credit as a security deposit, which is recorded as restricted cash in the accompanying consolidated balance sheets. The Company began to occupy this office space in April 2016, with rental payments beginning in the third quarter of 2016. In February 2026, FBIO entered into a sublease agreement with a third party for the entirety of the New York City office space subject to the Office Agreement. The Company remains obligated under the Office Agreement to pay its respective share of the rent and other related costs through the expiration of the lease term. Under the terms of the arrangement, the Company may be required to fund its proportionate share of any shortfall between the head lease obligations and sublease income. This transaction is expected to significantly reduce the Company’s net rent expense prospectively.

In October 2021, the Company finalized a five-year lease for office space in North Carolina (the NC Lease). The Company estimates an average annual rental obligation of $0.2 million under the NC Lease. The Company took possession of this space in February 2022, with rental payments beginning in April 2022.

The present values of the Company's lease liability and corresponding Right-of-Use (ROU) asset are $8.1 million and $6.3 million, respectively, as of December 31, 2025. The Company's leases have remaining lease terms of two to six years. One lease has a renewal option to extend the lease for an additional term of two years. The following components of lease expense are included in the consolidated statements of operations for the year ended December 31, 2025.

Operating lease cost was $1.9 million, $2.3 million and $2.2 million for the years ended December 31, 2025, 2024 and 2023, respectively.

As of December 31, 2025, the weighted-average remaining operating lease term was 5.2 years and the weighted-average discount rate for operating leases was 10.10%. Cash paid for amounts included in the measurement of operating lease liabilities during the year ended December 31, 2025 was $2.1 million.

The balance sheet classification of lease liabilities was as follows:

	*December 31,*		*December 31,*
(in thousands)	*2025*		*2024*
Liabilities
Lease liability current portion	$	1,044	$	1,157
Lease liability non-current		7,021		8,133
Total lease liability	$	8,065	$	9,290

As of December 31, 2025, the maturities of lease liabilities were as follows:

	*Operating*
	*leases*
2026	$	2,080
2027		1,913
2028		1,827
2029		1,827
After 2030		2,889
Total lease payments		10,536
Less: interest		(2,471	)
Present value of lease liabilities(*)	$	8,065

(*) As the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date and considering the term of the lease to determine the present value of lease payments. The Company used the incremental borrowing rate of 10.25% on February 28, 2019, for operating leases that commenced prior to that date through December 31, 2021. The Company used an incremental borrowing rate of 5.65% for the NC lease.

Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2025

Accounting Policies [Abstract]

Liquidity and Capital Resources Policy [Policy Text Block]

LIQUIDITY AND CAPITAL RESOURCES

The Company's common stock is quoted on the Nasdaq Capital Market and trades under the symbol “TGTX.”

New Accounting Pronouncements, Policy [Policy Text Block]

RECENTLY ISSUED ACCOUNTING STANDARDS

Use of Estimates, Policy [Policy Text Block]

USE OF ESTIMATES

Cash and Cash Equivalents, Policy [Policy Text Block]

CASH AND CASH EQUIVALENTS

The Company considers liquid investments with original maturities of less than three months from the date of purchase to be cash and cash equivalents.

Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]

RESTRICTED CASH

Investment, Policy [Policy Text Block]

INVESTMENT SECURITIES

Concentration Risk, Credit Risk, Policy [Policy Text Block]

CREDIT RISK

Revenue [Policy Text Block]

REVENUE RECOGNITION

Subject to certain limitations, the Company’s return policy allows for eligible returns of commercial products sold for credit under the following circumstances:

●	receipt of damaged product;

●	shipment errors that were a result of an error by the Company;

●	expired product that is returned during the period beginning three months prior to the product’s expiration and ending six months after the expiration date;

●	product subject to a recall; and

●	product that the Company, at its sole discretion, has specified can be returned for credit.

As of December 31, 2025, the Company has experienced an immaterial amount of product revenue returns related to sales of BRIUMVI.

License Agreements –

Other Revenue

DEFERRED PRODUCT REVENUE

Accounts Receivable [Policy Text Block]

ACCOUNTS RECEIVABLE

Cost of Goods and Service [Policy Text Block]

COST OF REVENUE

Inventory, Policy [Policy Text Block]

INVENTORY

Research and Development Expense, Policy [Policy Text Block]

RESEARCH AND DEVELOPMENT COSTS

Income Tax, Policy [Policy Text Block]

INCOME TAXES

Share-Based Payment Arrangement [Policy Text Block]

STOCK-BASED COMPENSATION

Stockholders' Equity, Policy [Policy Text Block]

SHARE REPURCHASES

Earnings Per Share, Policy [Policy Text Block]

NET INCOME PER COMMON SHARE

The following table summarizes the Company's potentially dilutive securities at December 31, 2025, 2024 and 2023:

	*December 31,*
	*2025*		*2024*		*2023*
Unvested restricted stock		12,011,850		10,343,555		8,139,037
Options		4,204,816		4,470,216		4,697,029
Warrants		165,214		165,214		312,272
Shares issuable upon note conversion		23,095		21,973		20,902
Total		16,404,975		15,000,958		13,169,240

The computation of basic and diluted earnings per share (EPS) is as follows:

	*Year ended*
	*December 31,*
(in thousands, except share and per share data)	*2025*		*2024*		*2023*
Net income		447,179		23,383		12,672
Weighted-average common shares outstanding		144,316,786		145,317,418		141,955,112
Dilutive effect of potential common shares		17,095,960		15,018,633		6,553,353
Weighted-average common shares outstanding assuming dilution		161,412,746		160,336,051		148,508,465

Net income per share - basic		3.10		0.16		0.09
Net income per share - diluted		2.77		0.15		0.09

Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]

LONG-LIVED ASSETS AND GOODWILL

Lessee, Leases [Policy Text Block]

LEASES

Leases with an initial term of 12 months or less are not recorded on the balance sheet, and the Company recognizes lease expense for these leases on a straight-line basis over the lease term.

Segment Reporting, Policy [Policy Text Block]

SEGMENT REPORTING

Note 2 - Revenue (Tables)

12 Months Ended

Dec. 31, 2025

Disaggregation of Revenue [Table Text Block]

(in thousands)	*Year ended December 31,*
	*2025*		*2024*		*2023*
Total product revenue, net	$	606,928	$	313,728	$	92,005
License Revenue		152		152		140,153
Milestone Revenue		—		12,500		—
Royalty Revenue		5,615		801		—
Other Revenue		3,592		1,823		1,504
Total Revenue	$	616,287	$	329,004	$	233,662

Disaggregation of Revenue by Product and Geography [Table Text Block]

(in thousands)	Year ended December 31,
	2025		2024		2023
BRIUMVI
U.S.	$	594,105	$	310,023	$	88,786
International		12,823		3,705		3,219
Worldwide	$	606,928	$	313,728	$	92,005

Schedules of Concentration of Risk, by Risk Factor [Table Text Block]

	*Twelve months ended December 31,*
	*2025*			*2024*			*2023*
Customer 1		42	%		42	%		41	%
Customer 2		26	%		29	%		31	%
Customer 3		18	%		15	%		16	%
Customer 4		12	%		14	%		13	%

	*Twelve months ended December 31,*
	*2025*			*2024*
Customer 1		38	%		32	%
Customer 2		18	%		25	%
Customer 3		27	%		25	%
Customer 4		15	%		17	%

Note 7 - Loan Payable - Schedule of Loan Payable (Details) - The First Amendment Term Loan [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Debt Instrument, Face Amount	$ 250,000	$ 250,000
Add: Accreted Liability of final payment fee	0	0
Long-Term Debt, Gross	250,000	250,000
Less: unamortized debt issuance costs	(4,355)	(5,571)
Long-term Debt, Before Repayments	245,645	244,429
Less: principal payments	0	0
Total loan payable	245,645	244,429
Less: current portion	0	0
Loan payable non-current	$ 245,645	$ 244,429

Note 9 - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Net operating loss carryforwards	$ 275,710	$ 294,046
Research and development credit	58,045	50,693
Noncash compensation	15,400	12,267
Capitalized R&D Expenses	14,753	49,681
Other	27,966	10,335
Gross deferred tax assets	391,874	417,022
Other	(3,897)	(2,408)
Net deferred tax assets, excluding valuation allowance	387,977	414,614
Less valuation allowance	(39,977)	(414,614)
Net deferred tax assets	$ 348,000	$ 0

Note 2 - Revenue - Disaggregation of Revenue By Product and Geography (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Revenue	$ 616,287	$ 329,004	$ 233,662
Product [Member]
Revenue	606,928	313,728	92,005
Briumvi Ublituximab [Member] \| Product [Member] \| UNITED STATES
Revenue	594,105	310,023	88,786
Briumvi Ublituximab [Member] \| Product [Member] \| International [Member]
Revenue	12,823	3,705	3,219
Briumvi Ublituximab [Member] \| Product [Member] \| Worldwide [Member]
Revenue	$ 606,928	$ 313,728	$ 92,005

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-7

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4

Cash and cash equivalents

Consolidated Balance Sheets as of December 31 - USD ($)
$ in Thousands

Dec. 31, 2025

Dec. 31, 2024

Current assets:

$ 79,148

$ 179,894

Short-term investment securities

62,822

131,106

Accounts receivable, net

305,628

129,185

Inventory

125,586

110,458

Other current assets

57,580

15,716

Total current assets

630,764

566,359

Restricted cash

1,342

1,298

Long-term investment securities

59,136

808

Right of use assets

6,278

7,151

Deferred tax assets

348,000

Long-term Inventory

15,689

Other noncurrent assets

^[1]

2,044

2,074

Total assets

1,063,253

577,690

Current liabilities:

Accounts payable and accrued expenses

107,508

58,296

Other current liabilities

^[1]

2,124

4,627

Lease liability – current portion

1,044

1,157

Deferred revenue - current portion

^[1]

21,234

11,414

Accrued compensation

21,850

15,185

Total current liabilities

153,760

90,679

Deferred revenue, non-current portion

8,807

12,085

Loan payable – non-current

245,645

244,429

Lease liability – non-current

7,021

8,133

Total liabilities

415,233

355,326

Commitments and contingencies

Stockholders’ equity:

Common stock, $0.001 par value per share (190,000,000 and 190,000,000 shares authorized, 158,849,596 and 156,204,159 shares issued, 155,305,953 and 155,836,256 shares outstanding at December 31, 2025 and December 31, 2024, respectively)

159

156

Additional paid-in capital

1,830,110

1,760,396

Treasury stock, at cost, 3,543,643 and 367,903 shares at December 31, 2025 and December 31, 2024

(100,234)

(8,994)

Accumulated deficit

(1,082,015)

(1,529,194)

Total stockholders’ equity

648,020

222,364

Total liabilities and stockholders’ equity

$ 1,063,253

$ 577,690

[1]	Amounts as of December 31, 2023 have been reclassified to conform to current period presentation.

Note 5 - Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2025

Fair Value, Liabilities Measured on Recurring and Nonrecurring Basis [Table Text Block]

	*Financial liabilities at fair value as of December 31, 2025*
(in thousands)	*Level 1*		*Level 2*		*Level 3*		*Total*

Equity Investments	$	1,323	$	—	$	—	$	1,323
Total Assets	$	1,323	$	—	$	—	$	1,323

Forward Contract Liabilities		—		1,412		—		1,412
5% Notes	$	—	$	—	$	689	$	689
Total	$	—	$	1,412	$	689	$	2,101

	Financial liabilities at fair value as of December 31, 2024
	Level 1		Level 2		Level 3		Total

Equity Investments	$	371	$	—	$	—	$	371
Total Assets	$	371	$	—	$	—	$	371

Forward Contract Liabilities	$	—	$	3,129	$	—	$	3,129
5% Notes	$	—	$	—	$	661	$	661
Total Liabilities	$	—	$	3,129	$	661	$	3,790

Insider Trading Policies and Procedures	12 Months Ended
Insider Trading Policies and Procedures	Dec. 31, 2025
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted [Flag]	true

Note 9 - Income Taxes

12 Months Ended

Dec. 31, 2025

Income Tax Disclosure [Text Block]

NOTE 9 – INCOME TAXES

The components of net income before taxes are as follows:

	*For the year ended December 31,*
(in thousands)	*2025*			*2024*			*2023*

Domestic	$	107,739		$	26,470		$	13,583
Foreign		(349	)		(876	)		(521	)
Net income before taxes	$	107,390		$	25,594		$	13,062

Income tax (benefit) expense consists of the following:

	*For the year ended December 31,*
(in thousands)	*2025*			*2024*		*2023*
Current:
Federal	$	—		$	—	$	—
State		8,211			2,211		390
Foreign		—			—		—
Total current tax expense	$	8,211		$	2,211	$	390

Deferred:
Federal	$	(335,077	)	$	—	$	—
State		(12,923	)		—		—
Foreign		—			—		—
Total deferred tax (benefit) expense	$	(348,000	)	$	—	$	—

Income tax (benefit) expense	$	(339,789	)	$	2,211	$	390

The Inflation Reduction Act of 2022 (“IRA”) was enacted on August 16, 2022. The IRA provided for a Corporate Alternative Minimum Tax (“Corp AMT”), applicable to tax years beginning after December 31, 2022. The Corp AMT will impose a 15% tax on companies with adjusted financial statement income of over $1 billion for U.S. based organizations. At this time, it is not anticipated that the Corp AMT will be applicable for the Company.

On July 4, 2025, the One Big Beautiful Bill Act (the OBBBA) was enacted in the United States. Among other changes, the OBBBA modifies key business tax provisions, including restoring 100% bonus depreciation under Section 168(k), reverting to the higher, EBITDA-based, business interest expense limitation under Section 163(j) and reinstatement of expensing domestic research and development costs including those previously capitalized under Section 174.

Beginning in 2025 annual reporting, the Company adopted ASU 2023-09 prospectively. See Note 1 - Organization and Summary of Significant Accounting Policies - Recently Issued Accounting Standards for additional details on the adoption of ASU 2023-09. A reconciliation of the U.S. federal statutory income tax rate to our effective tax rate for the year ending December 31, 2025 is as follows:

	*For the Year Ended*
	*December 31, 2025*
(in thousands)	*Tax Effect*			*Effective Tax Rate*

U.S. federal statutory income tax rate	$	22,552			21.0	%
State and local income tax, net of federal income tax effect		(6,440	)		(6.0	)%
Tax credits:
Research and development (R&D) tax credit		(7,352	)		(6.8	)%
Changes in valuation allowance		(357,904	)		(333.3	)%
Nontaxable or nondeductible items:
Officer compensation limit		6,213			5.8	%
Excess tax benefit on stock-based compensation		(8,118	)		(7.6	)%
Other		324			0.3	%
Other adjustments:
Limitation to tax attribute utilization		9,477			8.8	%
Other		1,459			1.4	%
Tax effect and effective tax rate	$	(339,789	)		(316.4	)%

Income tax expense differed from amounts computed by applying the US federal income tax rate of 21% for the years ending December 31, 2024 and 2023, to pretax income as follows:

	For the year ended December 31,
(in thousands)	2024			2023

Income before income taxes, as reported in the consolidated statements of operations	$	25,594		$	13,062

Computed “expected” tax benefit	$	5,375		$	2,743

Increase (decrease) in income taxes resulting from:
State and local taxes		780			(700	)
Research and development credits		(4,637	)		(3,402	)
Officer Compensation Limitation		2,164			(740	)
Provision-to-return		11,733			(9,235	)
Prior period state tax benefit		(3,508	)		—
Other		646			245
Stock options		(1,602	)		(10,616	)
Change in state tax rates		(4,970	)		4,141
Change in the balance of the valuation allowance for deferred tax assets		(3,770	)		17,954
	$	2,211		$	390

Cash paid for income taxes, net of refunds received, by jurisdiction for the years ended December 31, 2025 are as follows:

	*For the year ended December 31,*
(in thousands)	*2025*

Federal	$	300
State:
California		710
Kentucky		1,100
Mississippi		500
Tennessee		4,519
Other		750
Foreign		—

Cash paid for income taxes, net of refunds received	$	7,879

Our deferred tax assets (liabilities) are as follows:

(in thousands)	*2025*			*2024*
Deferred tax assets:
Net operating loss carryforwards	$275,710			$294,046
Research and development credit	58,045			50,693
Noncash compensation	15,400			12,267
Capitalized R&D Expenses	14,753			49,681
Other	27,966			10,335
Gross deferred tax assets		391,874			417,022
Deferred tax liabilities:
Other		(3,897	)		(2,408	)
Net deferred tax assets, excluding valuation allowance		387,977			414,614
Less valuation allowance	(39,977		)	(414,614		)
Net deferred tax assets	$	348,000		$	—

As of December 31, 2025, the Company has U.S. federal net operating loss (NOL) carryforwards of approximately $1.1 billion and research and development credit carryforwards (R&D credits) of approximately $58.0 million. For income tax purposes, these NOLs and R&D credits will expire in various amounts starting in 2029 and through 2046, respectively. NOLs generated after 2017 do not expire. The Tax Reform Act of 1986 contains provisions which limit the ability to utilize net operating loss carryforwards and R&D credit carryforwards in the case of certain events including significant changes in ownership interests. Stock issuance activities may have resulted in a “change in ownership” as defined by IRC Section 382 of the Internal Revenue Code of 1986, as amended. Accordingly, a portion of the Company’s NOLs have been identified as subject to annual limitations in reducing any future year’s taxable income. The Company has recorded approximately $9.5 million of tax expense to reflect this limitation. In addition, a portion of the R&D Credit carryforwards may be subject to annual limitations in reducing any future year’s tax.

A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized. In determining the need for a valuation allowance, management reviews both positive and negative evidence, including current and historical results of operations, future income projections and the overall prospects of our business. Based on the relevant weight of positive and negative evidence, including improved and sustained profitability trends as well as consideration of the Company's expected future taxable earnings, the Company concluded that it is more likely than not that its U.S. federal and certain state deferred tax assets are realizable at December 31, 2025. The Company continues to maintain a full or partial valuation allowance against certain state attributes as of December 31, 2025, because the Company concluded it is not more likely than not to be realized, as the Company expects certain state attribute generation in future years to exceed its ability to use these deferred tax assets. The valuation allowance for deferred tax assets was approximately $40.0 million and $414.6 million as of December 31, 2025 and 2024, respectively.

The Company files income tax returns in the U.S Federal and various state and local jurisdictions. With certain exceptions, the Company is no longer subject to U.S. Federal and state income tax examinations by tax authorities for years prior to 2022. However, NOLs and tax credits generated from those prior years could still be adjusted upon audit.

The Company would recognize interest and penalties, if any, to uncertain tax position in income tax expense in the statement of operations. There was no accrual for interest and penalties related to uncertain tax positions for 2025.

The entire disclosure for income tax.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 740
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477617/942-740-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 740
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478822/944-740-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477891/740-270-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-13

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/740/tableOfContent

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-14

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-21

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482603/740-30-50-2

Note 2 - Revenue - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Revenue	$ 616,287	$ 329,004	$ 233,662
Product [Member]
Revenue	606,928	313,728	92,005
License Revenue [Member]
Revenue	152	152	140,153
Milestone [Member]
Revenue	0	12,500	0
Royalty [Member]
Revenue	5,615	801	0
Other Revenue [Member]
Revenue	$ 3,592	$ 1,823	$ 1,504

Lease liability current portion

Note 8 - Leases - Schedule of Lease Cost (Details) - USD ($)
$ in Thousands

Dec. 31, 2025

Dec. 31, 2024

$ 1,044

$ 1,157

Lease liability non-current

7,021

8,133

Total lease liability

$ 8,065

^[1]

$ 9,290

[1]

Note 9 - Income Taxes (Tables)

12 Months Ended

Dec. 31, 2025

Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]

	*For the year ended December 31,*
(in thousands)	*2025*			*2024*			*2023*

Domestic	$	107,739		$	26,470		$	13,583
Foreign		(349	)		(876	)		(521	)
Net income before taxes	$	107,390		$	25,594		$	13,062

Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]

	*For the year ended December 31,*
(in thousands)	*2025*			*2024*		*2023*
Current:
Federal	$	—		$	—	$	—
State		8,211			2,211		390
Foreign		—			—		—
Total current tax expense	$	8,211		$	2,211	$	390

Deferred:
Federal	$	(335,077	)	$	—	$	—
State		(12,923	)		—		—
Foreign		—			—		—
Total deferred tax (benefit) expense	$	(348,000	)	$	—	$	—

Income tax (benefit) expense	$	(339,789	)	$	2,211	$	390

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]

	*For the Year Ended*
	*December 31, 2025*
(in thousands)	*Tax Effect*			*Effective Tax Rate*

U.S. federal statutory income tax rate	$	22,552			21.0	%
State and local income tax, net of federal income tax effect		(6,440	)		(6.0	)%
Tax credits:
Research and development (R&D) tax credit		(7,352	)		(6.8	)%
Changes in valuation allowance		(357,904	)		(333.3	)%
Nontaxable or nondeductible items:
Officer compensation limit		6,213			5.8	%
Excess tax benefit on stock-based compensation		(8,118	)		(7.6	)%
Other		324			0.3	%
Other adjustments:
Limitation to tax attribute utilization		9,477			8.8	%
Other		1,459			1.4	%
Tax effect and effective tax rate	$	(339,789	)		(316.4	)%

	For the year ended December 31,
(in thousands)	2024			2023

Income before income taxes, as reported in the consolidated statements of operations	$	25,594		$	13,062

Computed “expected” tax benefit	$	5,375		$	2,743

Increase (decrease) in income taxes resulting from:
State and local taxes		780			(700	)
Research and development credits		(4,637	)		(3,402	)
Officer Compensation Limitation		2,164			(740	)
Provision-to-return		11,733			(9,235	)
Prior period state tax benefit		(3,508	)		—
Other		646			245
Stock options		(1,602	)		(10,616	)
Change in state tax rates		(4,970	)		4,141
Change in the balance of the valuation allowance for deferred tax assets		(3,770	)		17,954
	$	2,211		$	390

Schedule of Cash Taxes Paid [Table Text Block]

	*For the year ended December 31,*
(in thousands)	*2025*

Federal	$	300
State:
California		710
Kentucky		1,100
Mississippi		500
Tennessee		4,519
Other		750
Foreign		—

Cash paid for income taxes, net of refunds received	$	7,879

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]

(in thousands)	*2025*			*2024*
Deferred tax assets:
Net operating loss carryforwards	$275,710			$294,046
Research and development credit	58,045			50,693
Noncash compensation	15,400			12,267
Capitalized R&D Expenses	14,753			49,681
Other	27,966			10,335
Gross deferred tax assets		391,874			417,022
Deferred tax liabilities:
Other		(3,897	)		(2,408	)
Net deferred tax assets, excluding valuation allowance		387,977			414,614
Less valuation allowance	(39,977		)	(414,614		)
Net deferred tax assets	$	348,000		$	—

Note 3 - Investment Securities

12 Months Ended

Dec. 31, 2025

Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]

NOTE 3 – INVESTMENT SECURITIES

The Company's investments securities as of December 31, 2025 and 2024 primarily consist of government debt securities that are classified as held-to-maturity. Held-to-maturity securities are recorded at amortized cost.

The following tables summarize the Company's held-to-maturity securities at December 31, 2025 and 2024:

	*December 31, 2025*
	*Amortized*		*Gross*		*Gross*
	*cost, as*		*unrealized*		*unrealized*		*Estimated*
(in thousands)	*adjusted*		*holding gains*		*holding losses*		*fair value*
Short-term obligations of domestic governmental agencies (maturing between January 2026 and December 2026) (held-to-maturity)	$	62,822	$	130	$	—	$	62,952
Long-term obligations of domestic governmental agencies (maturing between January 2027 and November 2027) (held-to-maturity)		57,541		201		—		57,742
Total held-to-maturity investment securities	$	120,363	$	331	$	—	$	120,694

	*December 31, 2024*
	*Amortized*		*Gross*		*Gross*
	*cost, as*		*unrealized*		*unrealized*		*Estimated*
	*adjusted*		*holding gains*		*holding losses*		*fair value*
Short-term obligations of domestic governmental agencies (maturing between January 2025 and December 2025) (held-to-maturity)	$	131,106	$	64	$	—	$	131,170
Total held-to-maturity investment securities	$	131,106	$	64	$	—	$	131,170

Included in long-term investments on the consolidated balance sheets are the Company’s equity securities held in connection with the Precision License Agreement. See Note 5 - Fair Value Measurements for a description of the Precision License Agreement and additional information on the Company's equity investments.

Note 10 - License Agreements (Details Textual) - USD ($) $ in Thousands					1 Months Ended	12 Months Ended			168 Months Ended
	Feb. 10, 2025	Jan. 07, 2025	Jan. 07, 2024	Jul. 28, 2023	Dec. 31, 2012	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2025	Jan. 31, 2012
Income Tax Expense (Benefit)						$ (339,789)	$ 2,211	$ 390
License and Collaboration Agreements, One-time, Non-refundable Payment						616,300
Precision BioSciences, Inc. [Member]
Investment Purchased Balance Shares (in shares)		220,712
License Agreement, Share Price, Trading Days (Day)		30 days
Precision BioSciences, Inc. [Member] \| Maximum [Member]
Investment Purchased Balance Shares (in shares)			2,920,816
L F B License Agreement [Member]
License And Collaboration Agreement, Expenses Incurred									$ 31,000
Accounts Payable						0			0
L F B License Agreement [Member] \| License Agreement Terms [Member]
Finite-Lived Intangible Asset, Useful Life (Year)										15 years
Royalty Expense						61,300	30,700	8,700
Accrued Royalties						19,200			19,200
Sublicense Agreement With Ildong Pharmaceutical Co [Member]
Upfront Fee Received From Sub License					$ 2,000
Income Tax Expense (Benefit)					300
License Revenue						200	200	$ 200
Deferred Revenue						0	200		0
Additional Amount Receivable on Achievement of Pre-specified Milestones					$ 5,000
Sublicense Agreement With Ildong Pharmaceutical Co [Member] \| License Agreement Terms [Member]
Finite-Lived Intangible Asset, Useful Life (Year)					15 years
Commercialization Agreement With Neuraxpharm [Member]
Deferred Revenue						30,000			30,000
Additional Amount Receivable on Achievement of Pre-specified Milestones				$ 492,500
License and Collaboration Agreements, One-time, Non-refundable Payment				$ 140,000
Royalty Percentage on Net Product Sales				30.00%
Revenues						5,600	$ 800
Commercialization Agreement With Neuraxpharm [Member] \| Accounts Receivable [Member]
Deferred Revenue						$ 1,800			$ 1,800
Briumvi Ublituximab [Member] \| Product [Member]
Product Sales, Net Related to Performance Obligations				$ 12,500
Precision License Agreement [Member]
License Agreement, Amount Paid Upfront			$ 7,500
License Agreement, Amount Paid Upfront, Cash			5,250
License Agreement, Amount Paid Upfront, Equity Investment			2,250
License Agreement, Deferred Payment			$ 2,500
License Agreement, Percentage of Premium on Equity Investment			100.00%
License Agreement, Share Price, Trading Days (Day)			30 days
License Agreement, Additional Milestone Payments			$ 288,000
Term After First Commercial Sale (Year)			10 years
Strategic Platform License Agreement with MaxCyte, Inc. [Member]
License Agreement, Amount Paid Upfront	$ 1,000
License Agreement, Additional Milestone Payments	13,000
Licensing Agreement, Annual License Fee	$ 200
License Agreement, Term (Year)	10 years
License Agreement, Renewal Term (Year)	5 years
License Agreement, Written Notice Period (Day)	90 days

Note 5 - Fair Value Measurements - Schedule of Fair Value Measurements (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Equity Securities, FV-NI	$ 1,323	$ 371
Total Assets	1,323	371
Forward Contract Liabilities	1,412	3,129
5% Notes	689	661
Total	2,101	3,790
Fair Value, Inputs, Level 1 [Member]
Equity Securities, FV-NI	1,323	371
Total Assets	1,323	371
Forward Contract Liabilities	0	0
5% Notes	0	0
Total	0	0
Fair Value, Inputs, Level 2 [Member]
Equity Securities, FV-NI	0	0
Total Assets	0	0
Forward Contract Liabilities	1,412	3,129
5% Notes	0	0
Total	1,412	3,129
Fair Value, Inputs, Level 3 [Member]
Equity Securities, FV-NI	0	0
Total Assets	0	0
Forward Contract Liabilities	0	0
5% Notes	689	661
Total	$ 689	$ 661

Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).

Fair value portion of notes payable.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-SubTopic 10
-Topic 210
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-11

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-11

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-10

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(19))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Consolidated Statements of Operations for the Years Ended December 31 - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Revenue:
Revenue	$ 616,287	$ 329,004	$ 233,662
Costs and expenses:
Cost of revenue	100,714	38,486	14,131
Research and development:
Noncash compensation	16,618	11,160	13,010
Other research and development	143,597	83,131	63,182
Total research and development	160,215	94,291	76,192
Selling, general and administrative:
Noncash compensation	48,053	31,381	24,923
Other selling, general and administrative	183,981	122,917	97,783
Total selling, general and administrative	232,034	154,298	122,706
Total costs and expenses	492,963	287,075	213,029
Operating income	123,324	41,929	20,633
Other expense (income):
Interest expense	26,727	24,028	12,615
Other income	(10,793)	(7,693)	(5,044)
Total other expense	15,934	16,335	7,571
Net income before taxes	107,390	25,594	13,062
Income tax benefit (expense)	339,789	(2,211)	(390)
Net income	$ 447,179	$ 23,383	$ 12,672
Net income per common share:
Basic (in dollars per share)	$ 3.1	$ 0.16	$ 0.09
Diluted (in dollars per share)	$ 2.77	$ 0.15	$ 0.09
Weighted-average shares outstanding:
Basic (in shares)	144,316,786	145,317,418	141,955,112
Diluted (in shares)	161,412,746	160,336,051	148,508,465
Product [Member]
Revenue:
Revenue	$ 606,928	$ 313,728	$ 92,005
License [Member]
Revenue:
Revenue	$ 9,359	$ 15,276	$ 141,657

Note 11 - Related Party Transactions (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Costs and Expenses, Related Party	$ 1.2	$ 1.3	$ 0.9

Note 5 - Fair Value Measurements (Details Textual) $ / shares in Units, $ in Thousands			1 Months Ended		12 Months Ended
	Jan. 07, 2025 USD ($) shares	Jan. 07, 2024 USD ($) $ / shares shares	Feb. 28, 2024	Mar. 31, 2010 USD ($) $ / shares	Dec. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)
Payments to Acquire Equity Securities, FV-NI					$ 1,250	$ 1,375	$ (0)
Manhattan and Ariston Pharmaceuticals Merger [Member]
Notes Issued				$ 15,500
Debt Instrument, Term (Year)				5 years
Debt Instrument, Interest Rate, Stated Percentage				5.00%
Debt Instrument, Convertible, Conversion Price (in dollars per share) \| $ / shares				$ 1,125
Precision BioSciences, Inc. [Member] \| Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio			30
Precision BioSciences, Inc. [Member]
Investment Purchased Balance Shares (in shares) \| shares	220,712
Investment Purchased Balance Price Per Share (in dollars per share) \| $ / shares		$ 0.77
Payments to Acquire Equity Securities, FV-NI	$ 2,500
License Agreement, Payment, Percentage of Weighted Average Share Price	200.00%
License Agreement, Share Price, Trading Days (Day)	30 days
Equity Method Investments, Fair Value Disclosure	$ 1,400
Precision BioSciences, Inc. [Member] \| Maximum [Member]
Investment Purchased Balance Shares (in shares) \| shares		2,920,816
Precision License Agreement [Member]
License Agreement, Amount Paid Upfront		$ 7,500
License Agreement, Amount Paid Upfront, Cash		5,250
License Agreement, Amount Paid Upfront, Equity Investment		$ 2,250
License Agreement, Share Price, Trading Days (Day)		30 days
License Agreement, Milestone Stock Payment		$ 2,300			$ 1,400

Note 3 - Investment Securities - Schedule of Investment Securities (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Amortized cost, as adjusted	$ 120,363	$ 131,106
Gross unrealized holding gains	331	64
Gross unrealized holding losses	0	0
Estimated fair value	120,694	131,170
US Government Agencies Debt Securities [Member] \| Short-Term Investments [Member]
Amortized cost, as adjusted	62,822	131,106
Gross unrealized holding gains	130	64
Gross unrealized holding losses	0	0
Estimated fair value	62,952	$ 131,170
US Government Agencies Debt Securities [Member] \| Long Term Investments [Member]
Amortized cost, as adjusted	57,541
Gross unrealized holding gains	201
Gross unrealized holding losses	0
Estimated fair value	$ 57,742

Fair value of investment in debt security measured at amortized cost (held-to-maturity).

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-11

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-11

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E

Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (aa)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5A

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(6))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Operating Lease, Liability

Note 8 - Leases (Details Textual)
$ in Thousands

1 Months Ended

12 Months Ended

Oct. 31, 2021

USD ($)

Oct. 31, 2014

USD ($)

ft²

Dec. 31, 2025

USD ($)

Dec. 31, 2024

USD ($)

Dec. 31, 2023

USD ($)

Dec. 31, 2021

Feb. 28, 2019

Restricted Cash

$ 1,342

$ 1,298

$ 1,285

8,065

^[1]

9,290

Operating Lease, Right-of-Use Asset

6,278

7,151

Operating Lease, Cost

$ 1,900

$ 2,300

$ 2,200

Operating Lease, Weighted Average Remaining Lease Term (Year)

5 years 2 months 12 days

Operating Lease, Weighted Average Discount Rate, Percent

10.10%

10.25%

Operating Lease, Payments, Use

$ 2,100

The North Carolina Lease [Member]

Average Annual Rental Payments

$ 200

Operating Lease, Weighted Average Discount Rate, Percent

5.65%

Office Agreement with Fortress Biotech [Member]

Percentage of Occupancy

45.00%

Area of Real Estate Property (Square Foot) | ft²

24,000

Lessee, Operating Lease, Term of Contract (Year)

15 years

Average Annual Rental Payments

$ 1,800

Office Agreement with Fortress Biotech [Member] | Deposit for Office Agreement [Member]

Restricted Cash

$ 1,300

Office Agreement [Member]

Lessee, Operating Lease, Renewal Term (Year)

5 years

2 years

Office Agreement [Member] | Minimum [Member]

Lessee, Operating Lease, Remaining Lease Term (Year)

2 years

Office Agreement [Member] | Maximum [Member]

Lessee, Operating Lease, Remaining Lease Term (Year)

6 years

[1]

Note 2 - Revenue (Details Textual) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Accounts Receivable [Member]
Gross Net Accruals	$ 20.5	$ 11.1
Accounts Payable and Accrued Liabilities [Member]
Gross Net Accruals	$ 40.9	$ 20.9

Note 4 - Inventory (Tables)

12 Months Ended

Dec. 31, 2025

Schedule of Inventory, Current [Table Text Block]

	*December 31, 2025*			*December 31, 2024*
Raw Materials	$	12,960		$	28,151
Work in Process		112,397			68,369
Finished Goods		22,089			13,938
Inventory, gross		147,446			110,458
Inventory Reserve		(6,171	)		—
Inventory, net	$	141,275		$	110,458

Reported As:
Inventory	$	125,586		$	110,458
Long-term Inventory		15,689			—
Total Inventory	$	141,275		$	110,458

Note 12 - Commitments and Contingencies (Details Textual) $ in Millions	Dec. 31, 2025 USD ($)
Purchase Obligation	$ 327.9
Purchase Obligation, to be Paid, Year One	102.3
Purchase Obligation, to be Paid, Year Two	109.1
Purchase Obligation, to be Paid, Year Three	$ 116.5

Note 1 - Organization and Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2025

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

	*December 31,*
	*2025*		*2024*		*2023*
Unvested restricted stock		12,011,850		10,343,555		8,139,037
Options		4,204,816		4,470,216		4,697,029
Warrants		165,214		165,214		312,272
Shares issuable upon note conversion		23,095		21,973		20,902
Total		16,404,975		15,000,958		13,169,240

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	*Year ended*
	*December 31,*
(in thousands, except share and per share data)	*2025*		*2024*		*2023*
Net income		447,179		23,383		12,672
Weighted-average common shares outstanding		144,316,786		145,317,418		141,955,112
Dilutive effect of potential common shares		17,095,960		15,018,633		6,553,353
Weighted-average common shares outstanding assuming dilution		161,412,746		160,336,051		148,508,465

Net income per share - basic		3.10		0.16		0.09
Net income per share - diluted		2.77		0.15		0.09

Consolidated Statements of Stockholders' Equity for the Years Ended December 31 (Parentheticals) $ in Millions	12 Months Ended
	Dec. 31, 2023 USD ($)
Offering costs	$ 0.8

Note 9 - Income Taxes - Income Before Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Domestic	$ 107,739	$ 26,470	$ 13,583
Foreign	(349)	(876)	(521)
Net income before taxes	$ 107,390	$ 25,594	$ 13,062

Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-21

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(11))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 14: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

Note 8 - Leases (Tables)

12 Months Ended

Dec. 31, 2025

Lease, Cost [Table Text Block]

	*December 31,*		*December 31,*
(in thousands)	*2025*		*2024*
Liabilities
Lease liability current portion	$	1,044	$	1,157
Lease liability non-current		7,021		8,133
Total lease liability	$	8,065	$	9,290

Schedule of Balance Sheet Classification of Operating Lease [Table Text Block]

	*Operating*
	*leases*
2026	$	2,080
2027		1,913
2028		1,827
2029		1,827
After 2030		2,889
Total lease payments		10,536
Less: interest		(2,471	)
Present value of lease liabilities(*)	$	8,065

Note 9 - Income Taxes - Cash Taxes Paid (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Federal	$ 300
Foreign	0
Cash paid for income taxes, net of refunds received	7,879	$ 500	$ 0
California Franchise Tax Board [Member]
State	710
Kentucky Department of Revenue [Member]
State	1,100
Mississippi Department of Revenue [Member]
State	500
Tennessee Department of Revenue [Member]
State	4,519
Other State Departments of Revenue [Member]
State	$ 750

Document And Entity Information - USD ($)	12 Months Ended
Document And Entity Information - USD ($)	Dec. 31, 2025	Feb. 25, 2026	Jun. 30, 2025
Document Information [Line Items]
Entity Central Index Key	0001001316
Entity Registrant Name	TG THERAPEUTICS, INC.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2025
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2025
Document Transition Report	false
Entity File Number	1-32639
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	36-3898269
Entity Address, Address Line One	3020 Carrington Mill Blvd, Suite 475
Entity Address, City or Town	Morrisville
Entity Address, State or Province	NC
Entity Address, Postal Zip Code	27560
City Area Code	212
Local Phone Number	554-4484
Title of 12(b) Security	Common Stock, par value $0.001
Trading Symbol	TGTX
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Document Financial Statement Error Correction [Flag]	false
Entity Shell Company	false
Entity Public Float			$ 2,500,000,000
Entity Common Stock, Shares Outstanding		159,688,256
Auditor Name	KPMG LLP
Auditor Location	New York, NY
Auditor Firm ID	185

Insider Trading Arrangements	3 Months Ended	12 Months Ended
Insider Trading Arrangements	Dec. 31, 2025	Dec. 31, 2025
Trading Arrangements, by Individual [Table]
Material Terms of Trading Arrangement [Text Block]		ITEM 9B. OTHER INFORMATION. Securities Trading Plans of Directors and Executive Officers During the three months ended December 31, 2025, none of our directors or executive officers adopted or terminated a Rule 10b5-1 trading arrangement (as defined in Item 408(a)(1)(i) of Regulation S-K) or adopted or terminated a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K) for the purchase or sale of the Company’s securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false

Note 12 - Commitments and Contingencies

12 Months Ended

Dec. 31, 2025